Phase I/II Study of RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
Phase: PHASE1
Conditions: Bladder Cancer
Sponsor: Memorial Sloan Kettering Cancer Center

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 1 of 62 
 
 
 
 
 
 
 
 
Phase I/II Study of Everolimus and Intravesical Gemcitabine in BCG-Refractory 
Primary or Secondary Carcinoma In Situ of the Bladder 
MSKCC THERAPEUTIC/DIAGNOSTIC PROTOCOL 
 
 
Principal Investigator/Department: 
Guido Dalbagni, MD 
Department of Surgery, 
Urology Service 
Co-Principal 
Investigator(s)/Department: 
Matthew I. Milowsky, MD 
Dean F. Bajorin, MD 
Department of Medicine, 
Genitourinary Service 
Department of Medicine, 
Genitourinary Service 
Investigator(s)/Department: 
Bernard Bochner, MD 
S. Machele Donat, MD 
Jonathan Coleman, MD 
Vincent Laudone, MD 
Paul Russo, MD 
Harry Herr, MD 
Jaspreet S. Sandhu, MD 
Andrew Vickers, PhD 
Hikmat Al-Ahmadie, MD 
Marcia Kalin, MD 
Rana Kaplan, MD 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Urology Service 
Department of 
Epidemiology-Biostatistics 
Department of Pathology 
Department of Medicine, 
Endocrinology Service 
Department of Medicine, 
Pulmonary Service 
Consenting Professional(s)/Department: Guido Dalbagni, MD 
Bernard Bochner, MD 
S. Machele Donat, MD 
Jonathan Coleman, MD 
Vincent Laudone, MD 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 2 of 62 
 
 
 
Paul Russo, MD 
 
Jaspreet S. Sandhu, MD 
Matthew I. Milowsky, MD 
Dean F. Bajorin, MD 
Urology Service 
Department of Surgery, 
Urology Service 
Department of Surgery, 
Urology Service 
Department of Medicine, 
Genitourinary Service 
Department of Medicine, 
Genitourinary Service 
 
 
 
 
Please Note: A Consenting Professional must have completed the mandatory Human 
Subjects Education and Certification Program. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Memorial Sloan-Kettering Cancer Center 
1275 York Avenue 
New York, New York 10065 
 
 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 3 of 62 
 
 
Table of Contents 
 
1.0 PROTOCOL SUMMARY AND/OR SCHEMA ................................................................................4 
2.0 OBJECTIVES AND SCIENTIFIC AIMS .........................................................................................5 
3.0 BACKGROUND AND RATIONALE ..............................................................................................6 
3.1 mTOR Pathway and Mechanism of Action .................................................................... 6 
3.2 Preclinical Studies ........................................................................................................... 8 
3.2.1 Preclinical Safety ................................................................................................. 9 
3.3 Clinical Experience .......................................................................................................... 9 
3.3.1 Everolimus Pharmacokinetics.............................................................................. 9 
3.3.2 Everolimus Pharmacodynamic Studies ............................................................. 10 
3.3.3 Clinical Experience with Everoli mus .................................................................. 10 
3.4 Gemcitabine ....................................................................................................................12 
3.4.1 Preclinical Studies with Intravesical Gemcitabine.............................................. 13 
3.4.2 Clinical Experience with Intravesical Gemcitabine ............................................ 13 
3.5 Carcinoma In Situ (0is)...................................................................................................15 
3.5.1 Natural History of Bladder Cancer ..................................................................... 15 
3.5.2 Recurrence ........................................................................................................ 16 
3.5.3 Progression........................................................................................................ 16 
3.5.4 Current Concepts in Intravesical Therapy ......................................................... 16 
3.6 Rationale for this Study .................................................................................................18 
 
4.0 OVERVIEW OF STUDY DESIGN/INTERVENTION ....................................................................18 
4.1 Design..............................................................................................................................18 
4.1.2 Proposed Correlative Studies ............................................................................ 20 
4.2 Intervention .....................................................................................................................21 
 
5.0 THERAPEUTIC/DIAGNOSTIC AGENTS ....................................................................................21 
5.1 Everolimus...................................................................................................................... 21 
5.1.1 Drug Dispensing/Administration ........................................................................ 21 
5.1.2 Storage and Stability.......................................................................................... 22 
5.1.3 Source of Drug................................................................................................... 22 
5.1.4 Drug Accountability ............................................................................................ 22 
5.1.5 Toxicity............................................................................................................... 22 
5.2 Gemcitabine ................................................................................................................... 23 
5.2.1 Investigational Drug Description ........................................................................ 23 
5.2.2 Availability .......................................................................................................... 23 
5.2.3 Administration .................................................................................................... 23 
5.2.4 Toxicity............................................................................................................... 23 
 
6.0 CRITERIA FOR SUBJECT ELIGIBILITY ....................................................................................23 
6.1 Subject Inclusion Criteria ..............................................................................................23 
6.2 Subject Exclusion Criteria .............................................................................................25 
 
7.0 RECRUITMENT PLAN.................................................................................................................26 
8.0 PRETREATMENT EVALUATION................................................................................................26 
9.0 TREATMENT/INTERVENTION PLAN .........................................................................................27 
9.1 Phase I Schedule and Dose Administration ................................................................ 28 
9.1.1 Dose Escalation Scheme................................................................................... 28 
9.1.2 Maximum Tolerated Dose.................................................................................. 29 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 4 of 62 
 
 
9.2 Phase II Dose Administration ....................................................................................... 29 
9.2.1 Interruption or Discontinuation of Treatment During Phase II............................ 29 
9.3 Dose Modification .......................................................................................................... 30 
9.3.1 Monitoring of Everolimus Suspected Toxicities ................................................. 32 
9.3.2 Management of Stomatitis/Oral Mucositis/Mouth Ulcers ................................... 32 
9.3.3 Management of Hyperlipidemia and Hyperglycemia ......................................... 32 
9.3.4 Management of Non-Infectious Pneumonitis ..................................................... 33 
9.3.5 Management of Hepatitis B ............................................................................... 34 
9.3.6 Management of Hepatitis C ............................................................................... 36 
9.4 Concomitant Therapy .................................................................................................... 36 
 
10.0 EVALUATION DURING TREATMENT/INTERVENTION ..........................................................39 
11.0 TOXICITIES/SIDE EFFECTS.....................................................................................................45 
11.1 Known Undesirable Side Effects of Everolimus ....................................................... 45 
12.0 CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSESSMENT ............................ 47 
 
13.0 CRITERIA FOR REMOVAL FROM STUDY ..............................................................................47 
14.0 BIOSTATISTICS ........................................................................................................................47 
15.0 RESEARCH PARTICIPANT REGISTRATION AND RANDOMIZATION PROCEDURES .......49 
15.1 Research Participant Registration ..............................................................................49 
15.2 Randomization ..............................................................................................................49 
 
16.0 DATA MANAGEMENT ISSUES ................................................................................................49 
16.1 Quality Assurance ........................................................................................................50 
16.2 Data and Safety Monitoring .........................................................................................50 
 
17.0 PROTECTION OF HUMAN SUBJECTS ...................................................................................50 
17.1 Privacy ...........................................................................................................................50 
17.2 Serious Adverse Event (SAE) Reporting....................................................................51 
17.2.1 Serious Adverse Event (SAE) Reporting to Novartis .......................................51 
 
18.0 INFORMED CONSENT PROCEDURES ...................................................................................52 
18.1 Research Authorization ...............................................................................................53 
19.0 REFERENCES ...........................................................................................................................53 
 
20.0 APPENDICES ............................................................................................................................57 
 
 
1.0PROTOCOL SUMMARY AND/OR SCHEMA 
 
This is a Phase I/II trial of Everolimus in combination with intravesical gemcitabine in patients with 
BCG-refractory TisN0M0. 
 
Phase I: We will evaluate 3 dose levels of continuous Everolimus (Everolimus dose levels: Dose 
level 1: 5 mg every other day, Dose level 2: 5 mg daily, and Dose level 3: 10 mg daily) in 
combination with a fixed dose of intravesical gemcitabine at a dose of 2000 mg twice weekly for 3 
weeks, followed by a week of rest from gemcitabine—this constitutes one 28-day cycle—and a 
second course of intravesical gemcitabine followed by a week of rest from gemcitabine. Everolimus 
will be continued for 12 months in the patients who achieve a CR. 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 5 of 62 
 
 
Agent 
Cycle 1 
(Weeks +2 days) 
Cycle 2 
(Weeks +2 days) 
Cycles 3-12 
(+7 days) 
1 
2 
3 
4* 
5 
6 
7 
8* 
Gemcitabine 
X 
X 
X 
X 
X 
X 
Everolimus 
X 
X 
X 
X 
X 
X 
X 
X 
*One w eek of rest from intravesical gemcitabine. There is no w eek of rest from Everolimus, w hich is taken continuously. 
 
Phase II: Patients will receive continuous Everolimus administered at the dose determined from the 
Phase I part of the study and intravesical gemcitabine at a dose of 2000 mg twice weekly for 3 
weeks followed by a week of rest from gemcitabine—this constitutes one 28-day cycle—and a 
second course of intravesical gemcitabine followed by a week of rest from gemcitabine. Everolimus 
will be continued for 12 months in the patients who achieve a CR. Patients demonstrating a CR (by 
cystoscopy and cytology) will be observed with serial cystoscopies every 3 months. 
 
Agent 
Cycle 1 
(Weeks +2 days) 
Cycle 2 
(Weeks +2 days) 
Cycles 3-12 
(+7 days) 
1 
2 
3 
4* 
5 
6 
7 
8* 
Gemcitabine 
X 
X 
X 
X 
X 
X 
Everolimus 
X 
X 
X 
X 
X 
X 
X 
X 
*One w eek of rest from intravesical gemcitabine. There is no w eek of rest from Everolimus, w hich is taken continuously. 
 
 
 
 
2.0OBJECTIVES AND SCIENTIFIC AIMS 
 
Primary 
 
The primary endpoints are: 
 
a.) Phase I - to establish the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) 
of Everolimus given in conjunction with intravesical gemcitabine. 
b.) Phase II - to determine the proportion of patients who are free of disease at 1 year following 
start of therapy. 
 
Secondary 
 
The secondary endpoints are: 
 
a.) To determine the CR rate (by cytology and cystoscopy) in patients receiving Everolimus in 
combination with intravesical gemcitabine. 
b.) To determine the survival of patients treated with Everolimus in combination with intravesical 
gemcitabine. 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 6 of 62 
 
 
c.) To evaluate for activated mTOR pathway markers as well as PTEN status and AKT 
activation in all pretreatment specimens and analysis of posttreatment specimens when 
available. 
 
 
 
3.0BACKGROUND AND RATIONALE 
 
Everolimus is a novel oral derivative of rapamycin. 
 
Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ 
transplantation and has obtained marketing authorization (Certican®) for prophylaxis of rejection in 
renal and cardiac transplantation in a number of countries, including the majority of the European 
Union. Everolimus has been in development for patients with various malignancies since 2002. 
 
Everolimus is being investigated as an anticancer agent based on its potential to act: 
 
• 
Directly on the tumor cells by inhibiting tumor cell growth and proliferation 
 
• 
Indirectly by inhibiting angiogenesis, leading to reduced tumor vascularity (via potent inhibition of 
tumor cell HIF-1 activity, vascular endothelial growth factor (VEGF) production, and VEGF- 
induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid 
tumor growth is well established, and the mammalian target of rapamycin (mTOR) pathway has 
been implicated in the regulation of tumor production of proangiogenic factors as well as 
modulation of VEGFR signaling in endothelial cells. 
 
At weekly and daily schedules and at various doses explored, Everolimus is generally well tolerated. 
The most frequent adverse events (rash, mucositis, fatigue, and headache) associated with 
Everolimus therapy are manageable. Noninfectious pneumonitis has been reported with mTOR 
inhibitors, but is commonly low grade and reversible. 
 
 
3.1 mTOR Pathway and Mechanism of Action 
 
At the cellular and molecular levels, Everolimus acts as a signal transduction inhibitor. Everolimus 
selectively inhibits mTOR, a key and highly conservative serine-threonine kinase, which is present in 
all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, 
angiogenesis, and cell survival. mTOR is the only currently known target of Everolimus.(1) 
 
mTOR is downstream of the PI3K/AKT pathway, a pathway known to be dysregulated in a wide 
spectrum of human cancers (e.g., through loss/mutation of the PTEN negative regulator, through 
PI3K mutation/amplification, through AKT/PKB overexpression/overactivation, and through 
modulation of tuberous sclerosis complex 1 and 2 (TSC1/TSC2) tumor suppressors). In addition, 
activation of the PI3K/AKT/mTOR pathway is frequently a characteristic of worsening prognosis 
through increased aggressiveness, resistance to treatment, and progression. 
 
The main known functions of mTOR include the following (1-2): 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 7 of 62 
 
 
• 
mTOR functions as a sensor of mitogens, growth factors, and energy and nutrient levels, 
facilitating cell-cycle progression from G1 to S phase in appropriate growth conditions. 
• 
The PI3K/mTOR pathway itself is frequently activated in many human cancers, and oncogenic 
transformation may sensitize tumor cells to mTOR inhibitors. 
• 
Through the inactivation of the eukaryotic translation initiation factor (elf)4E-binding proteins (4E- 
BP1) and activation of the 40S ribosomal S6 kinases (i.e., p70S6K1), mTOR regulates the 
translation of important messages, including those encoding the HIF-1 proteins, c-myc, ornithine 
decarboxylase, and cyclin D1, as well as ribosomal proteins themselves. 
• 
The activation of the mTOR pathway leads to the increased production of proangiogenic factors 
(i.e., VEGF) in tumors and to tumor, endothelial, and smooth muscle cell growth and 
proliferation. 
• 
The regulation of mTOR signaling is complex and involves positive regulators, such as AKT that 
phosphorylate and inactivate negative regulators such as the TSC1/TSC2. 
 
 
 
mTOR is represented by 2 structurally and functionally distinct multiprotein signaling complexes, 
mTOR complex 1 (mTORC1, rapamycin sensitive) and mTOR complex 2 (mTORC2, rapamycin 
insensitive).(3) 
 
mTORC1 is mainly activated via the PI3 kinase pathway through AKT (also known as PKB, protein 
kinase B) and the TSC1/TSC2.(2) Activated AKT phosphorylates TSC2, which lead to the 
dissociation of the TSC1/TSC2 complex, thus inhibiting the ability of TSC2 to act as a GTPase- 
activating protein. This allows Rheb, a small G-protein, to remain in a GTP-bound state and to 
activate mTORC1. AKT can also activate mTORC1 by phosphorylation of proline-rich AKT substrate 
of 40 kilodaltons (PRAS40), thereby relieving the PRAS40-mediated inhibition of mTORC1.(4-5) 
 
mTORC2 is activated through a currently unknown mechanism, possibly by receptor tyrosine kinase 
(RTK) signaling.(4) It has been suggested that mTORC2 phosphorylates and activates a different 
pool of AKT that is not upstream of mTORC1. PH domain leucine-rich repeat protein phosphatase 
(PHLPP) plays a role of a negative regulator. mTORC2 is rapamycin insensitive and is required for 
the organization of the actin cytoskeleton.(3) 
 
mTORC1-mediated signaling is subject to modulation by the macrocyclic lactone rapamycin and its 
derivatives, such as Everolimus. Once these agents bind to the 12 kDa cytosolic FK506-binding 
protein 12 (FKBP12), an immunophilin, the resulting rapamycin-FKBP12 complexes bind to a 
specific site near the catalytic domain of mTORC1 and inhibit phosphorylation of mTOR substrates. 
As a consequence, downstream signaling events involved in regulation of the G1 to S-phase 
transition are inhibited. This mechanism is thought to be responsible for the immunosuppressive 
effects of rapamycin as well as its putative antineoplastic activity.(6) As many cancers are 
characterized by dysregulation of G1 transit (e.g., overexpression of cyclin or cyclin-dependent 
kinases), inhibition of mTOR becomes an intriguing target for inducing cytostasis.(2) 
 
 
3.2 Preclinical Studies 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 8 of 62 
 
 
 
 
Preclinical investigations have demonstrated that Everolimus is a potent inhibitor of the proliferation 
of a range of human tumor cell lines in vitro, with IC50s ranging from sub/low nanomolar (nM) to µM 
concentrations, concentrations capable of being reached in patients at the doses used in clinical 
trials. 
 
Everolimus was shown to have activity in human tumor cell lines originating from lung, breast, 
prostate, colon, kidney, melanoma, and glioblastoma. Everolimus was also shown to have activity in 
human pancreatic neuroendocrine cells, where induction of apoptosis was reported,(7) as well as in 
acute myeloid leukemia cells,(8) adult T-cell leukemia cells,(9) diffuse large B-cell lymphoma cells 
(DLBCL),(10) pancreatic tumor cells,(11) ovarian cancer cells,(12-13) and hepatocellular carcinoma 
cells.(14) 
 
As a single agent, Everolimus inhibited proliferation in 3 mantle cell lymphoma cell lines (Jeko1, 
SP49, and NCEB1) approximately 40% to 65% compared to control cells. This was associated with 
G1 cell-cycle arrest and reduced phosphorylation of the mTOR downstream target, 4E-BP1.(15) 
 
In a clonogenic assay using cells from 81 patient-derived tumor xenografts never cultured in vitro (11 
human tumor types, with 3 to 24 tumors each: bladder, colon, gastric, non-small cell lung cancer 
(NSCLC) [adeno, squamous epithelium, and large cell], small cell lung cancer (SCLC), breast, 
ovarian, pancreatic, renal, melanoma, and pleuramesothelioma), Everolimus inhibited colony 
formation in a concentration-dependent manner. In addition, normal hematopoietic stem cells were 
insensitive to Everolimus, with an IC50 about 15-fold higher than the tumor lines. 
 
Everolimus also inhibits the proliferation of human umbilical vein endothelial cells (HUVECS), with 
particular potency against VEGF-induced proliferation. The inhibition of endothelial proliferation and 
antiangiogenic activity of Everolimus was confirmed in vivo, as Everolimus selectively inhibited 
VEGF-dependent angiogenic response. Mice with primary and metastatic tumors treated with 
Everolimus showed a significant reduction in blood vessel density when compared to controls at well 
tolerated doses. Additionally, activity in a VEGF-impregnated s.c. implant model of angiogenesis and 
reduced vascularity (vessel density) of Everolimus -treated tumors (murine melanoma) provided 
evidence of in vivo effects of angiogenesis. 
 
Everolimus also inhibits tumor growth in vivo in xenografted, syngeneic, and orthotopic animal 
models, residing longer in tumor tissue than in plasma and demonstrating high tumor penetration in a 
rat pancreatic tumor model. These effects occurred within the dose range of 2.5 to 10 mg/kg p.o. 
daily. Typically, the antitumor activity of Everolimus monotherapy was that of reducing tumor growth 
rates rather than producing regressions or stable disease. 
 
Everolimus, administered p.o., was a potent inhibitor of tumor growth and well tolerated in: 
 
• 
an s.c. mouse xenograft model, established from a variety of tumor cell lines of diverse 
histotypes (NSCLC, pancreatic, colon, melanoma, epidermoid), including a P-gp170 
overexpressing multidrug-resistant tumor line 
• 
a series of low-passage tumor xenografts established directly from human tumor material, 
maintained only in vivo and considered highly predictive of therapeutic outcome in patients. 
These included breast (5 lines), colorectal (9 lines), gastric (3 lines), lung (22 lines, including 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 9 of 62 
 
 
adenocarcinomas, epidermoid cell, large cell and small cell histotypes), melanoma (6 lines), 
ovarian (4 lines), pancreatic (3 lines), and renal (6 lines). 
• 
in 2 syngeneic models (CA20948 rat pancreatic, B16/Bl6 mouse orthotopic melanoma) 
Taken together, these data indicate the broad antiproliferative potential of Everolimus. 
It is not clear which molecular determinants predict responsiveness of tumor cells to Everolimus. 
Molecular analysis has revealed that relative sensitivity to Everolimus in vitro correlates with the 
degree of phosphorylation (activation) of the AKT/PKB protein kinase and the S6 ribosomal protein. 
PTEN status alone may not be predictive of Everolimus relative in vitro sensitivity; however, in some 
cases (i.e., GBM) there is also a correlation with PTEN status. 
 
In preclinical models, the administration of Everolimus is associated with reduction of protein 
phosphorylation in target proteins downstream of mTOR, notably phosphorylated S6 (pS6) and p4E- 
BP1, and occasionally with an increase in phosphorylation AKT (pAKT). 
 
 
3.2.1 Preclinical Safety 
 
In safety pharmacologic studies, Everolimus was devoid of relevant effects on vital functions, 
including the cardiovascular, respiratory, and nervous systems. Everolimus had no influence on QT 
interval prolongation. Furthermore, Everolimus showed no antigenic potential. Although Everolimus 
passes the blood-brain barrier, there was no indication of relevant changes in the behavior of 
rodents, even after single oral doses up to 2000 mg/kg or after repeated administration of up to 40 
mg/kg/day. Based on these findings, the potential of Everolimus to affect vital functions in patients is 
considered to be low. 
 
Everolimus is considered to have no genotoxicity or carcinogenicity potential. All significant adverse 
events observed in preclinical toxicology studies with Everolimus in mice, rats, monkeys, and 
minipigs were consistent with its anticipated pharmacologic action as an antiproliferative and 
immunosuppressant, and were, at least in part, reversible after a 2- or 4-week recovery period, with 
the exception of the changes in male reproductive organs, most notably testes. Ocular effects 
(lenticular disorders) observed in rats were not observed in any other species and are considered to 
be a species-specific disorder. 
 
 
3.3 Clinical Experience 
 
3.3.1 Everolimus Pharmacokinetics 
 
Everolimus is rapidly absorbed with a median tmax of 1 to 2 hours. The bioavailability of the drug is 
believed to be 11% or greater. The area under the curve (AUC)0-τ is dose-proportional over the dose 
range between 5 mg and 70 mg in the weekly regimen and 5 mg and 10 mg in the daily regi men. Cmax  
is dose-proportional between 5 mg and 10 mg for both the weekly and daily regimens. At doses of 20 
mg/week and higher, the increase in Cmax is less than dose-proportional. The coefficient of 
variation between patients is approximately 50%. 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 10 of 62 
 
 
Trough levels (24 hours postdose) correlate well with AUC0-τ at steady state during daily 
administration. 
 
In whole blood, at a daily dose of 10 mg, about 20% of Everolimus is confined in plasma, with 26% 
being unbound. The remaining 80% is sequestered in blood cells. 
 
Everolimus is extensively metabolized in the liver and eliminated in the bile. Major metabolites are 
inactive. Elimination half-life is approximately 30 hours. The clearance of Everolimus is 
approximately halved in patients with mild-moderate hepatic impairment (Child-Pugh Class A or B), 
while renal impairment has little or no impact on the pharmacokinetics of Everolimus. 
 
Age, weight, and sex in the adult population do not affect the pharmacokinetics of Everolimus to a 
clinically relevant extent. The clearance of Everolimus is reduced in children. Pharmacokinetic 
characteristics are not notably different between Caucasian and Japanese subjects, whereas in 
Black patients, population pharmacokinetic studies have shown an average 20% higher clearance. 
 
A high-fat meal altered the absorption of Everolimus, with a 1.3-hour delay in tmax, a 60% reduction in 
Cmax, and a 16% reduction in AUC. 
 
Everolimus is a substrate of cytochrome P450 3A4 isoenzyme (CYP3A4) and a substrate and 
moderate inhibitor of the multidrug efflux pump P-glycoprotein (P-gp, MDR1, or ABCB1). Hence, its 
metabolism is sensitive to drugs that modify these enzymes (substrates, inducers, or inhibitors of 
these enzymes). Competitive inhibition could occur when Everolimus is combined with drugs that 
are also CYP3A4 or P-gp substrates. 
 
 
 
3.3.2 Everolimus Pharmacodynamic Studies 
 
Pharmacokinetic/pharmacodynamic modeling based on inhibition of the biomarker p70S6 kinase 1 
[S6K1] in peripheral blood mononuclear cells (PBMC) suggests that 5 mg to 10 mg daily should be 
an adequate dose to produce a high degree of sustained target inhibition ([Study C2101] / [Study 
2102]).(16) Furthermore, molecular pharmacodynamic (MPD) studies, using immunohistochemistry 
(IHC) in biopsied tumor tissue, assessed the degree of inhibition and its duration for pS6, p4E-BP1, 
and pAKT expression with the daily and weekly dosing. There was high inhibition of the downstream 
markers S6K1 and 4E-BP1 at 5mg/day, which was complete at 10 mg/day, and preliminary results 
suggest an increase in pAKT expression, with maximal effect at 10 mg daily ([Study C2107]).(17) 
 
 
3.3.3 Clinical Experience with Everolimus 
 
Since 1996, Everolimus has been investigated as a component of multidrug immunosuppression in 
solid organ transplantation. On July 8, 2003, the European Union approved the use of Everolimus, 
under the trade name Certican®, as prophylaxis of organ rejection in adult patients receiving an 
allogeneic renal or cardiac transplant. The most frequent adverse drug reactions in this setting are 
highly specific to the transplant context. However, certain events are generalizable, most notably 
myelosuppression, skin disorders, and increases in blood lipid levels. 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 11 of 62 
 
 
In March 2009, the United States Food and Drug Administration (FDA) approved Everolimus for the 
treatment of advanced renal cell carcinoma (RCC) in patients with advanced RCC after treatment 
with sunitinib or sorafenib has failed. 
 
Everolimus has been in development for patients with cancer since 2002. As of August 31, 2008, 
approximately 4000 patients with various malignancies have been treated in Novartis-sponsored or 
non-Novartis-sponsored studies, and in 3 healthy volunteer clinical studies. Overall, Novartis 
sponsored a total of 28 studies of Everolimus administered either as single agent (n=13) or in 
combination with other antitumor agents (n=15). Ongoing or completed investigator-sponsored 
studies also enrolled over 1000 patients globally. 
 
Eight single-agent, Novartis-sponsored trials have been or are being conducted in various advanced 
malignancies. Five Phase I studies evaluated several escalating doses with either weekly or daily 
administration (Studies C2101/02, C2106, C2107, C1101) of Everolimus, with the objective to identify 
an optimal regimen and dosage based on safety, pharmacokinetics, and knowledge of the drug’s 
molecular effects on various tumors. The 10 mg/day and 50 mg to 70 mg/week dosages were 
proposed for further studies when using Everolimus as a single agent and as a target maximum 
dose in combination studies. In addition, 2 Phase I studies, one conducted in prostate cancer (Study 
C2106) and the other in Japanese patients with advanced cancers (Study C1101), evaluated the 
safety and the molecular changes in tumor associated with the administration of Everolimus. 
 
Two Phase II monotherapy studies were designed to evaluate the safety and efficacy of a single 
dose of 10 mg administered daily, including Study C2235 in advanced NSCLC (n=81) and Study 
C2239 in advanced pancreatic neuroendocrine tumors (n=160). 
 
A Phase III, randomized, double-blind, placebo-controlled study in patients with metastatic RCC who 
progressed on a VEGFR TK inhibitor (TKI) demonstrated that everolimus, administered daily at an 
oral dose of 10 mg, provides positive clinical benefit.(18) Median progression-free survival (PFS) 
was prolonged from 1.87 months for patients receiving placebo to 4.01 months for everolimus- 
treated patients, assessed by central independent review blinded to clinical data (hazard ratio, 0.30; 
95% CI, 0.22–0.40; p<0·0001). 
 
Updated results presented at the American Society of Clinical Oncology 2009 Genitourinary Cancers 
Symposium (19) demonstrated everolimus as having even greater superiority to placebo in the 
primary endpoint of PFS. Median PFS was prolonged from 1.9 months for patients receiving placebo 
to 4.9 months for everolimus-treated patients, assessed by central independent review blinded to 
clinical data (hazard ratio, 0.33; 95% CI, 0.25–0.43; p<0.001). 
 
Overall, the most frequent adverse effects suspected to be related to Everolimus have been 
stomatitis, rash, anemia, fatigue, asthenia, diarrhea, anorexia, nausea, hypercholesterolemia, 
mucosal inflammation, vomiting, hypertriglyceridemia, cough, peripheral edema, dry skin, epistaxis, 
pruritus, and dyspnea. The most common grade 3 or 4 adverse reactions suspected to be related to 
treatment were anemia, infections, hyperglycemia, stomatitis, fatigue, lymphopenia, 
hypercholesterolemia, pneumonitis, and elevated gamma-glutamyltransferase concentrations. 
Noninfectious low-grade (grade 1/2) pneumonitis has led to the development of treatment guidelines 
for the disorder. The primary dose-limiting toxicity (DLT) has been severe (grade 3) stomatitis and, 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 12 of 62 
 
 
occasionally, fatigue, hyperglycemia, and neutropenia. Further detailed information regarding 
Everolimus clinical development, safety, and efficacy is provided in the [Investigator’s Brochure]. 
 
 
 
The trial is looking at an active agent, namely gemcitabine in combination with a novel agent with 
pre-clinical data suggesting that urothelial cancer represents a rationale target for m-TOR inhibition. 
A trial at Memorial Sloan Kettering Cancer Center (MSKCC) (protocol 08-123) of Everolimus in 
patients with metastatic transitional cell carcinoma of the urothelium that has progressed after first- 
line therapy with a 2-month progression free survival endpoint is ongoing. 
 
 
 
At MSKCC, we performed an immunohistochemical (IHC) study to assess whether mTOR pathway 
markers are expressed in high-stage bladder urothelial carcinomas. The study was carried out on a 
tissue microarray of 92 cases of invasive urothelial carcinoma of the bladder (≥ pT2) using 
antibodies against phospho-S6 and phospho-4E BP1, both markers for an activated mTOR 
pathway. Staining was graded as 0 to 3+ (0=0-5%; 1+=6-25%; 2+=26-50%; and 3+=>50% tumor 
cells positive) for phsopho-S6 (cytoplasmic) and phospho-4E BP1 (cytoplasmic and/or nuclear). 
Presence of at least two evaluable cores from each tumor was required for inclusion in the final 
evaluation. The results of immunoreactivity in tumor cells demonstrated that mTOR pathway 
markers are overexpressed in invasive urothelial carcinoma of the bladder with correlation of 
expression seen within molecules of the mTOR pathway using Spearmans correlation coefficient 
(rho=0.411) (see table below).(34) This suggests that m-TOR targeted therapies may have activity in 
patients with urothelial carcinoma. 
 
Tumor cell immunoreactivity 
Antibody (# cases) 
Grade 0 (%) 
Grade 1+ (%) 
Grade 2+ (%) 
Grade 3+ (%) 
p-S6 (85) 
45 (53) 
11 (13) 
9 (11) 
20 (23) 
p-4E BP1 (84) 
25 (30) 
10 (12) 
17 (20) 
32 (38) 
 
3.4 Gemcitabine 
 
Gemcitabine (2',2'-difluoro-2' deoxycytidine; Gemzar, Eli Lilly and Co, Indianapolis, IN) is a novel 
deoxycytidine analog with a broad spectrum of antitumor activity. Gemcitabine has a molecular 
weight of 299.66, and after intracellular activation, the active metabolite is incorporated into DNA, 
resulting in inhibition of further DNA synthesis. Gemcitabine may also inhibit ribonucleotide 
reductase and cytidine deaminase as part of its cytotoxic activity.(20) Since its approval in 1996 by 
the FDA for the treatment of pancreatic cancer,(20-21) gemcitabine has been found to have effective 
antitumor activity against a broad spectrum of tumor types, including breast, ovarian, non-small cell 
lung, and bladder. Studies in patients with metastatic transitional cell carcinoma (TCC) of the 
bladder have reported overall response rates to single-agent gemcitabine that ranged from 22.5% in 
previously treated patients to 28% in those who were not previously treated.(22-24) These studies 
also reported that single-agent gemcitabine therapy was well tolerated and that the incidence of 
systemic side effects was low. A multicenter, randomized, Phase III study in patients with 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 13 of 62 
 
 
unresectable and metastatic bladder cancer demonstrated that a regimen consisting of gemcitabine 
plus cisplatin had a better tolerability and toxicity profile than the standard regimen of methotrexate, 
vinblastine, doxorubicin, and cisplatin (MVAC), although overall survival was similar in both treatment 
groups.(25) On the basis of its excellent clinical activity, patient tolerability, and chemical 
characteristics, gemcitabine represents a logical candidate for intravesical therapy. 
 
3.4.1 Preclinical Studies with Intravesical Gemcitabine 
 
We studied the toxicology and pharmacokinetics of gemcitabine delivered intravesically in dogs to 
provide the basis for subsequent clinical studies. 
 
Methods: Toxicology (n=6): The animals (in groups of 2) received 100 mg, 350 mg, or 1 g of 
gemcitabine intravesically on alternate days 3 times/week for 4 weeks. The animals were observed 
for signs of toxicity; gemcitabine levels and peripheral blood counts were taken 3 times weekly. 
Tetrahydrouridine (THU) was added to prevent ex vivo degradation of gemcitabine by cytidine 
deaminase. One dog from each group was euthanized at day 1 after the last dose and the other dog 
from each group at day 14. Full necropsy was performed in all animals. Urine specimens with and 
without THU were examined to exclude any degradation of the drug. Pharmacokinetics (n=5): 
Intravesical gemcitabine was given at 100 mg (n=2), 350 mg (equivalent to 1000mg/m2 human 
dose) (n=2), and 3.5 g (n=1). Intravenous gemcitabine was given at 350 mg (n=2). Serum samples 
were drawn at 30 minutes and at 1, 2, 4, and 8 hours. 
 
Results: Toxicology: 100 mg and 350 mg were well tolerated, with no demonstrable side effects. At 
350 mg, the white cell count nadir was 2.9 and 3.1 (x103µl) and the platelet count dropped to 97 and 
63 (x103/µl). Necropsy revealed normal bone marrow cellularity, normal bladder histology, and no 
other abnormalities. At 1000 mg, signs of severe toxicity were seen; these dogs received only 3 
doses. One dog died at day 3 following cessation of treatment and 1 was euthanized at day 5 due to 
febrile neutropenia. The necropsy was consistent with hemorrhagic cystitis and gastrointestinal 
toxicity. Pharmacokinetics: At 100 mg and 350 mg, significant systemic absorption of gemcitabine 
was seen, with peak serum levels observed at 1 hour and with detectable levels up to 8 hours 
following intravesical gemcitabine. For a given dose, the AUC for intravesical administration is 
approximately half that of the intravenous infusion. As the AUC is a better predictor of toxicity, it is 
concluded that the equivalent systemic dose, if given intravesically, would be half as toxic. 
 
 
3.4.2 Clinical Experience with Intravesical Gemcitabine 
 
We conducted a Phase I study of gemcitabine administered intravesically in 18 patients with TCC of 
the bladder refractory to Bacille Calmette-Guérin (BCG), and the results showed excellent tolerability 
to intravesical gemcitabine given twice a week.(26) The patients included 14 men and 4 women (4:1 
male/female ratio), with a median age of 74 years (range, 37–86 years). Stages of bladder cancer 
included refractory 0is in 12 patients and recurrent T1 carcinoma with or without 0is in 6 patients. 
Patients were previously treated with 1 to 4 courses of BCG, and 5 patients had been previously 
treated with intravesical chemotherapy, including mitomycin, valrubicin, thiotepa, and Adriamycin. 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 14 of 62 
 
 
Four intravesical dose levels of gemcitabine were evaluated: 500 mg, 1000 mg, 1500 mg, and 2000 
mg. Of the 18 eligible patients, 3 were enrolled at dose level I (500 mg), 6 at dose level II (1000 mg), 
3 at dose level III (1500 mg), and 6 at dose level IV (2000 mg). Intravesical gemcitabine was 
administered twice weekly in 2 courses of 3 weeks each, with 1 week of rest between courses, for a 
total of 12 instillations. At the end of 8 weeks, patients were evaluated for response. Patients who 
demonstrated CR (negative posttreatment cytology and cystoscopy) underwent close surveillance 
with serial cystoscopies at 3-month intervals. If recurrence was detected, 2 additional courses (3 
weeks each, separated by 1 week) of intravesical gemcitabine could be considered, followed by re- 
evaluation. For patients who did not achieve initial CR or who suffered a relapse, a radical 
cystectomy was recommended. 
 
Toxicity: Gemcitabine as an intravesical agent was well tolerated. The most commonly observed 
toxicities were as follows: At dose level I (500 mg; n=3), 1 patient had grade 1 nausea, and there was 
no urothelial toxicity. At dose level II (1000 mg; n=6), 4 patients experienced grade 2 urinary 
frequency (more than 2 times normal frequency or urination) and 1 experienced grade 3 urinary 
frequency (more than hourly urination with urgency); intermittent gross hematuria without clots was 
present in 3 patients, 2 patients experienced grade 1 nausea and fatigue, and 1 patient had a skin 
reaction that resembled a grade 3 hand-foot syndrome. At dose level III (1500 mg; n=3), minimal 
urinary symptoms were experienced by all 3 patients, but no systemic symptoms were observed. At 
dose level IV (2000 mg; n=6), urinary symptoms were minimal; grade 3 thrombocytopenia and 
neutropenia was seen in 1 patient, without infectious complications, but no grade 4 systemic 
toxicities were observed. DLT was not reached; 2000 mg was the highest soluble dose in 100 mL of 
sodium chloride. 
 
Pharmacokinetics: Levels of gemcitabine in the serum were evaluated at all 4 dose levels after the 
first, third, seventh, and ninth instillations. Serum levels of gemcitabine were detected at dose level 
IV (2000 mg) in 2 patients, including the patient who experienced grade 3 thrombocytopenia and 
neutropenia, but were undetectable at the first 3 dose levels (500, 1000, and 1500 mg). 
 
Based on the results of our Phase I study, we subsequently conducted a Phase II trial in patients 
with superficial TCC of the bladder who were refractory or intolerant to BCG therapy and who had 
refused cystectomy.(27) The patients included 22 men and 8 women (7:3 male/female ratio), with a 
median age of 70 years (range, 43–89 years). Stages of bladder cancer immediately before 
intravesical instillation included 0is in 23 patients, T1 in 3 patients, and incompletely resected high- 
grade Ta in patients. Of 30 patients, 27 were refractory to BCG and 3 were intolerant to BCG. 
 
Intravesical gemcitabine at a dose of 2000 mg was administered twice weekly in 2 courses of 3 
weeks each, with 1 week of rest between courses, for a total of 12 instillations. At the end of 8 
weeks, patients were evaluated for response. Patients who demonstrated CR (cytology and 
cystoscopy) underwent close surveillance with urine cytology and serial cystoscopies at 3- to 4- 
month intervals. For patients who did not achieve initial CR, a radical cystectomy was recommended. 
The median follow-up for all patients was 19 months (range, 0 to 35 months). Of the 
30 patients treated with intravesical gemcitabine, 15 (50%; 95% CI, 32%–68%) had CR; however, 
only 21% (95% CI, 0%–43%) of these patients were free of recurrence at 1 year. Therefore, of the 
total 30 patients treated with intravesical gemcitabine, only 10% (95% CI, 0%–21%) were free of 
recurrence at 1 year. Of the 15 patients who achieved CR, 14 were available for recurrence and 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 15 of 62 
 
 
progression analysis: 12 had tumor recurrence, with a median recurrence-free survival time of 3.6 
months (95% CI, 2.9–11.0 months), and 2 had no tumor recurrence at 23 and 29 months, 
respectively. Overall, 2 patients had progression to a higher stage while receiving gemcitabine 
therapy. The median follow-up for patients without progression or cystectomy was 19 months 
(range, 2 to 35 months). Of the 30 patients, 11 (37%) underwent a cystectomy after treatment with 
gemcitabine; 4 of these 11 patients had CR to the gemcitabine therapy. 
 
Toxicity: Gemcitabine as an intravesical agent was well tolerated in this Phase II study, with a 
reported toxicity similar to that of our Phase I study: grade 2 dysuria (occasional pain or difficulty 
urinating) in 3 patients, grade 3 dysuria (continuous difficulty urinating characterized by pain and 
frequency) in 6 patients, a rash on the glans penis in 1 patient, and cellulitis of the leg (requiring 
intravenous antibiotics) in 1 patient who was on immunosuppression therapy for a renal transplant. 
 
The efficacy, safety, and pharmacokinetics of intravesical gemcitabine have been evaluated in 2 
other Phase I studies, albeit using a less intensive weekly schedule. Laufer et al studied the weekly 
administration of gemcitabine in 15 patients who had recurrent TCC after intravesical therapy.(28) 
Levels of gemcitabine in the serum were low in patients receiving 40 mg/mL, and they were 
undetectable at concentrations of 5 mg/mL, 10 mg/mL, 15 mg/mL, and 20 mg/mL. Levels of the 
metabolite dFdU (difluorodeoxyuridine), however, were detectable in plasma of patients receiving 
gemcitabine at concentrations of 15 mg/mL or higher, which implies that the amount of gemcitabine 
absorbed at lower doses is minimal. Laufer and colleagues found that intravesical gemcitabine was 
well tolerated and had minimal toxicity, and 9 of the 13 patients available for assessment were free of 
recurrence at 12 weeks. In their Phase I study, De Berardinis et al found that at concentrations of 
40 mg/mL gemcitabine was systemically undetectable, but they were able to detect the inactive 
metabolite dFdU in plasma.(29) 
 
In our experience, substantial CR can be achieved initially in patients receiving intravesical 
gemcitabine, but the 1-year durable CR was only 10% as the majority of patients underwent a 
relapse within 12 months, which supports the concept of combining intravesical gemcitabine with 
other agents to improve the durability of CR. 
 
 
 
3.5 Carcinoma In Situ (0is) 
 
3.5.1 Natural History of Bladder Cancer 
 
More than 70,000 new cases of bladder cancer are diagnosed each year in the United States.(30) 
Seventy to 80% of bladder tumors are non-muscle invasive tumors (stage Ta, Tis, T1), 25% are 
muscle invasive (stage T2, T3), and 5% are metastatic. Sixty to 70% of non-muscle invasive tumors 
recur, while 20% to 30% progress to a higher stage or grade.(31) 
 
Superficial or non-muscle invasive urothelial bladder cancer (UBC) includes stages Ta, T1, and Tis 
(carcinoma in situ – 0is), with frequencies of 60%, 30%, and 10%, respectively. The term “non- 
muscle invasive bladder cancer” embraces a spectrum of tumors with varying degrees of clinical 
behavior. The low-grade Ta lesions commonly recur but rarely progress to muscle invasion. On the 
other hand, T1 tumors represent a heterogeneous population, including some of which behave in an 
indolent fashion and typically respond to conservative therapy, as well as others that behave more 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 16 of 62 
 
 
aggressively and progress to muscle invasion and even metastatic disease. At present, we lack the 
ability to predict the clinical behavior of T1 tumors prospectively. 
 
 
 
3.5.2 Recurrence 
 
Recurrence rate after transurethral resection (TUR) ranges from 30% to 90%, depending on size, 
site, multifocality, the presence of 0is, grade, and prior history of bladder cancer. The high 
recurrence rate and the unpredictability of the progression pattern of bladder cancer have led to the 
widespread use of intravesical therapy as a supplement to TUR. Non-muscle invasive UBC lends 
itself to intravesical therapy owing to direct contact of the chemotherapeutic agent with the bladder 
mucosa and tumor. Furthermore, some agents can be used at high doses, with minimal systemic 
side effects due to minimal absorption. 
 
In a prospective longitudinal study, the National Bladder Cancer Collaborative Group A (NBCCGA) 
identified a group of patients with superficial TCC treated solely by TUR and identified the factors 
implicated in tumor recurrence. In this study, size itself did not seem to be a factor unless it was 
greater than 5 cm. An increased recurrence rate occurred in patients with multiple tumors, Grade 3 
disease, concomitant 0is, lamina propria invasion, and positive cytology.(32) 
 
 
3.5.3 Progression 
 
Progression is defined as the development of muscle invasion or metastasis and occurs in 20% to 
30% of patients who present with superficial disease. The NBCCGA identified tumor grade, lamina 
propria invasion, and associated 0is as indicators of progression. Two percent of patients with grade 
1 tumors progressed compared to 11% with Grade 2 and 45% with Grade 3, with the majority 
progressing within 24 months of diagnosis.(32) Four percent of patients with Ta lesions progressed 
versus 30% with T1 tumors. Eight percent of tumors without mucosal abnormalities progressed 
versus 33% with moderate to severe dysplasia. In a compilation of data, Herr et al reported a 29% 
progression for T1 tumors and 40% for T1 G3. (33) It is clear that the poor prognosis of superficial 
TCC is predominantly due to patients with T1 disease. The high recurrence rate and the 
unpredictability of the progression pattern have led to the investigation of new approaches. 
 
 
3.5.4 Current Concepts in Intravesical Therapy 
 
Superficial bladder cancer lends itself to intravesical therapy due to the direct contact between the 
chemotherapeutic agent and the tumor. Furthermore, very high doses of some agents could be used 
with minimal systemic side effects due to the lack of absorption (e.g., mitomycin is given at a dose of 
40 mg weekly for 8 weeks). This led to the widespread use of intravesical therapy after resecting the 
papillary tumors endoscopically or documenting the presence of diffuse 0is. BCG, thiotepa, mitomycin 
C, and doxorubicin have been used as intravesical agents. The highest tumor-free success rate has 
been reported after intravesical BCG therapy. Multicenter studies have shown that thiotepa and 
doxorubicin are inferior to BCG in preventing tumor recurrences. In studies comparing mitomycin and 
BCG, initial tumor-free response rates are comparable for the 2 agents, with some studies suggesting 
an advantage for BCG therapy. In a randomized trial comparing BCG to no Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 17 of 62 
 
 
intravesical therapy, 38% of patients treated with BCG progressed at 10 years versus 63% for the 
control group. There was no significant difference between groups with regard to stage. Progression 
was defined as muscle invasion or metastatic disease. The median survival times for both groups 
have not been reached. Ten-year survival in BCG was 75% compared with 55% in the control group. 
Patients with an initial incomplete response to BCG have a poor outcome. The overall risk of 
progression is 95% at 5 years for 0is patients with an incomplete response but only 19% in those 
with an initial CR. Alternative therapies are needed for patients who fail BCG. Mitomycin C, with a 
15% response when given intravesically, is the most active chemotherapeutic agent. Despite this 
level of activity, mitomycin C has neither delayed progression nor preserving the bladder. Thus, 
more active agents need to be identified. 
 
BCG is associated with toxicity in the form of local complications, such as cystitis in 90% of patients, 
requiring interruption of treatment in 3.6%, hematuria in 9%, epididymitis in 0.4%, contracted bladder 
in 0.2%, granulomatous prostatitis in 0.9%, renal abscess in 0.1 %, and ureteral obstruction in 0.3%. 
Systemic complications represent the main concern in BCG-treated patients. Fever up to 38.5°C is 
frequently observed, pneumonia and hepatitis have been reported in 0.9% of patients, and sepsis in 
0.4%. 
 
Everolimus selectively inhibits mTOR (mammalian target of rapamycin), a serine-threonine kinase, 
which is present in all cells and a central regulator of protein synthesis and ultimately cell growth, 
proliferation, angiogenesis and survival.(1) mTOR is downstream of PI3K (phosphatidyl-inositol-3- 
kinase)/AKT, a pathway known to be dysregulated in a wide spectrum of human cancers through 
various potential mechanisms including loss/mutation of the PTEN (phosphatase and tensin homolog 
deleted on Chromosome 10) negative regulator, PI3K mutation/amplification, AKT/PKB 
overexpression/overactivation, and/or modulation of TSC1/TSC2 tumor suppressors. In addition, 
activation of the PI3K/AKT/mTOR pathway is frequently associated with increased aggressiveness, 
resistance to treatment and progression. Previous work has demonstrated the over-expression of 
activated mTOR pathway markers including phospho-S6 and phospho-4E BP1 in invasive urothelial 
carcinoma specimens.(34) Preclinical studies have demonstrated that that mutational activation of 
the PI3K pathway through loss of PTEN or activation of the serine/threonine kinase, AKT, makes 
tumor cells more sensitive to the anti-tumor effects of mTOR inhibitors.(35-38) These findings have 
provided the rationale to explore the anti-tumor activity of mTOR inhibitors in patients with PTEN- 
deficient tumors with a proof-of-concept phase 1 neoadjuvant trial of rapamycin in patients with 
recurrent glioblastoma whose tumors lacked PTEN expression demonstrating anticancer activity. 
(39) 
 
 
 
3.6 Rationale for this Study 
 
Rationale for this study includes the following: 
 
1) Standard management for patients with high-risk superficial disease who fail BCG therapy is 
removal of the bladder (cystectomy). There is a paucity of active agents for patients who fail 
intravesical BCG, none of which eliminates the need for cystectomy. 
 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 18 of 62 
 
 
2) Patients wish to avoid a cystectomy because cystectomy generally requires an external collecting 
device for urine, which is associated with poor self-image and quality of life. Surgery results in 
impotence in men due to the need to remove the prostate as part of the surgical procedure. 
 
3) The favorable activity of gemcitabine, including CR, when given systemically in metastatic 
urothelial carcinoma and transient CR when used intravesically for non-muscle-invasive UBC. 
 
4) The acceptable clinical toxicity profile of gemcitabine when given intravesically. 
 
5) The need to increase the durability of the response to intravesical chemotherapy. 
 
6) This proposed study targets patients with stage 0is UBC who have failed or have relapsed after 
intravesical BCG, the standard treatment for this stage of disease. Unfortunately, standard therapy is 
frequently ineffective in the setting of persistent or recurrent disease. Persistent or recurrent 0is after 
BCG is an ominous sign. Despite the poor prognosis, some patients refuse cystectomy because of 
quality of life concerns and request alternative treatment. The standard of care for patients who 
failed or did not respond to BCG has not changed in over 25 years and new approaches are needed 
for this patient population. 
 
7) Intravesical valrubicin is the only agent approved by the FDA. It is a modestly active agent in this 
setting, with a 21% CR rate reported in a Phase II study, and a 1-year durable CR of 13%. It is 
infrequently used in the urologic community because of the significant local toxicity and short 
durability of the response. 
 
8) We have shown that gemcitabine given twice weekly was associated with minimal bladder 
irritation and tolerable myelosuppression. We proceeded with a Phase II study, documenting a CR of 
50%. However, the 1-year durable CR was only 10%, suggesting a need for maintenance therapy. 
 
9) There is a clear need for novel agents in BCG-refractory 0is. Furthermore, an active agent that 
can be administered systemically has the added advantage of potentially treating upper tract 
disease, which occurs in 20% of this patient population. 
 
10) The mTOR inhibitor Everolimus has been shown to inhibit protein synthesis and growth of 
bladder cancer cells in vitro. Everolimus is efficacious in treating bladder cancer cells in vivo. mTOR 
inhibitors have also shown synergism with gemcitabine in pancreatic cell lines, supporting the 
concept of combination therapy using Everolimus with intravesical gemcitabine. 
 
 
 
4.0OVERVIEW OF STUDY DESIGN/INTERVENTION 
 
4.1Design 
 
Patient population 
 
Sample size: In Phase I, a minimum of 2 and a maximum of 18 patients will be accrued. In Phase II, a 
minimum of 33 and a maximum of 45 patients will be accrued (6 can be carried over from the MTD 
cohort of Phase I). 
 
Time required for accrual of all patients: 24 months (estimate) 
Average accrual rate per month: 1-2 patients 
Sites: Single institution (MSKCC) 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 19 of 62 
 
 
Recruitment plan: All MSKCC patients with stage TisN0M0 TCC of the bladder who have failed or 
relapsed after intravesical BCG will be offered the protocol. Both sexes and all racial and ethnic 
groups will be eligible to participate in this clinical trial, provided all the other eligibility criteria are 
met. The surgeons will meet weekly with the involved medical oncologists to discuss study patients. 
 
 
Phase I: 3 dose levels of continuous Everolimus (Everolimus dose levels: Dose level 1: 5 mg every 
other day, Dose level 2: 5 mg daily, and Dose level 3: 10 mg daily) in combination with a fixed dose 
of intravesical gemcitabine at a dose of 2000 mg twice weekly for 3 weeks, followed by a week of 
rest from gemcitabine—this is the first 28-day cycle—and a second course of intravesical 
gemcitabine, also followed by a week of rest from gemcitabine—the second 28-day cycle—will be 
evaluated using the DLT rules outlined below: 
 
Table 4.1-1 
Number of subjects with DLT 
Action 
0 of 3 subjects 
Escalate to next highest dose level and enroll up to 
3 subjects 
1 of 3 subjects 
Enroll up to 3 more subjects at the same dose level 
1 of 6 subjects 
Escalate to next highest dose level and enroll up to 
3 more subjects 
2 or 3 subjects in the first 3 
subjects 
De-escalate to lower dose level and enroll up to 6 
subjects 
≥ 2 of 6 subjects 
De-escalate to lower dose level and enroll up to 6 
subjects 
 
If 2 of the first 2 subjects have DLT, the enrollment of a third subject at the same dose level is not 
necessary. Similarly, if 2 of 4 subjects or 2 of 5 subjects have DLT, it is not necessary to enroll 
subsequent subjects at the same dose level.  All the Everolimus doses will be given in addition to 
intravesical Gemcitabine at the dose of 2,000mg in 100cc twice weekly. 
 
There will be no planned dose level below dose level 1. If ≥ 2 DLTs occur at dose level 1, then the 
study will be terminated. 
 
There will be no planned dose level beyond dose level 3. If no DLTs occur at dose level 3, the 
Phase II portion of the trial will be initiated. 
 
The MTD is the dose level at which no more than 1 out of 6 patients experience DLT. 
If ≥ 2 subjects at the first dose level experience DLT, then the study will be terminated and the 
combination of Everolimus at a dose of 5 mg every other day with intravesical gemcitabine at a dose 
of 2000 mg twice weekly will be considered unsafe in this population. 
 
Patients will be observed for DLTs through the 3rd cycle of treatment (the first three 28-day cycles) 
prior to dose escalation for the next dose level for the next cohort of patients. No intrapatient dose 
escalation will occur. DLTs will be defined as follows, using NCI Common Terminology Criteria for 
Adverse Events (CTCAE) version 4.0: 
 
1)  Any evidence of grade 3 or 4 toxicity under Renal and Urinary Disorders in CTCAE version 4.0. 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 20 of 62 
 
 
2)  Febrile neutropenia (absolute neutrophil count (ANC)) < 1000/μL plus oral temperature to 
38.5°C) 
 
3)  Grade 4 neutropenia (ANC <500/μL) for ≥ 7 days 
 
4)  Other grade 4 hematologic toxicity 
 
5)  Other nonhematologic grade 3 or 4 treatment-related toxicity, excluding nausea/vomiting, rash, 
untreated hyperlipidemia or grade 3 fatigue lasting ≤ 7 days. 
 
6)  Any nonhematologic toxicity requiring treatment delay for > 7 days during cycle 1. 
 
Phase II: Patients will receive continuous Everolimus administered at the dose determined from the 
Phase I part of the study and intravesical gemcitabine at a dose of 2000 mg twice weekly for 3 
weeks followed by a week of rest from gemcitabine—this is the first 28-day cycle—and a second 
course of intravesical gemcitabine followed by a week of rest from gemcitabine—this is the second 
28-day cycle. Everolimus will be continued for 12 months in the patients who achieve a CR. Patients 
demonstrating a CR (by cystoscopy and cytology) will be observed with serial cystoscopies every 3 
months. 
 
4.1.2 Proposed Correlative Studies 
 
1) Analysis of pretreatment tumor tissue specimens in all patients by immunohistochemistry markers 
of activated mTOR pathway phsopho-S6 and phospho-4E BP1 as well as PTEN, .phospho-AKT and 
PRAS 40, a downstream substrate of AKT. The total number of unstained slides required for this is 
10 unstained slides or 1 paraffin-embedded block. This will not require research biopsies. 
 
 
The staining will be performed at the Core Lab of MSKCC’s Department of Pathology. The stains will 
be evaluated by the GU pathologist on this protocol (Hikmat Al-Ahmadie) and the staining will be 
graded as 0 to 3+ (0 = 0-5%; 1+ = 6-25%; and 3+ = >50% tumor cells positive). 
 
2) Pretreatment tumor samples will be evaluated for PTEN and PIK3CA mutational status using 
bidirectional full length sequencing. This assay will be performed by either Sanger sequencing 
and/or the Sequenom technique at the DNA Sequencing Core Facility at MSKCC. This assay will 
require 2 curls of 10 microns of the formalin-fixed paraffin-embedded tumor tissue sections. 
 
 
4.2Intervention 
 
Everolimus administration 
 
The study drug Everolimus will be self-administered on an outpatient basis. The investigator will 
instruct the patient to take the study drug exactly as specified in the protocol. Patients will be 
required to maintain a pill diary (Appendix 1, Appendix 2, and Appendix 3). Everolimus will start on 
Cycle 1, Day 1 of intravesical therapy and will be taken continuously. 
 
Phase I: Everolimus will be administered as follows: 
Dose level 1: 5 mg every other day 
Dose level 2: 5 mg daily 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 21 of 62 
 
 
Dose level 3: 10 mg daily 
 
Phase II: Everolimus will be administered at the dose determined in Phase I. 
Gemcitabine administration 
• 
Patients will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72–96 hours 
between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from 
intravesical gemcitabine, course 2 will be administered, provided the treating physician notes 
acceptable patient tolerance. The total number of intravesical instillations will be 12. 
• 
All intravesical chemotherapy will be administered to the patient in the Urology Clinic on an 
outpatient basis and kept in the bladder for 1 hour. 
 
 
 
5.0THERAPEUTIC/DIAGNOSTIC AGENTS 
 
5.1 Everolimus 
Everolimus is a novel oral derivative of rapamycin. Everolimus will be administered orally 
continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be 
instructed to take Everolimus in the morning, at the same time each day. 
 
Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free 
meal. Dietary habits around the time of Everolimus intake should be as consistent as possible 
throughout the study. 
 
If vomiting occurs, no attempt should be made to replace the vomited dose. 
 
5.1.1 Drug Dispensing/Administration 
 
Administration will be performed on an outpatient basis. Everolimus will be dispensed as tablets at 
the beginning of each treatment cycle. In case of dose modification, patients will be asked to return 
all of their previously dispensed medication to the clinic and they will be dispensed new-strength 
tablets. 
 
All dosages prescribed and dispensed to the patient and all dose changes during the study must be 
recorded. 
 
Medication labels will comply with US legal requirements and will be printed in English. They will 
supply no information about the patient. The storage conditions for study drug will be described on 
the medication label. 
 
Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 
5mg strength. Tablets are blister-packed under aluminum foil in units of 10 tablets, which should be 
opened only at the time of administration as drug is both hygroscopic and light-sensitive. 
 
 
Amended: 1/11/11 

Page 22 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
5.1.2 Storage and Stability 
 
 
Current stability data permit a shelf life of either 36 months (for 5mg tablet variants based on solid 
dispersion dried by evaporation/drying oven) or 24 months (for 2.5mg, 5 mg and 10 mg tablet 
variants based on solid dispersion dried by paddle dryer), assuming correct storage below 30°C in 
the original double-sided aluminium blister packaging and protected from light and moisture. 
 
5.1.3 Source of Drug 
Novartis, Inc. will supply Everolimus free of charge. 
 
 
5.1.4 Drug Accountability 
All study drug supplies must be kept in a locked room with limited access. The study drug must not be 
used outside the context of this protocol. Under no circumstances should the investigator or other site 
personnel supply study drug to other investigators, patients, or clinic, or allow supplies to be 
used other than directed by this protocol without prior authorization from Novartis. 
 
 
The pharmacist will maintain a complete drug accountability record for each tablet strength with lot 
numbers of each drug received, including the number of bottles dispensed to each patient, the dates 
drug was dispensed, and the daily dose of Everolimus the patient received. The prescribed dose 
should also be recorded in the patient’s medical records. 
 
At the conclusion of the study, all unused Everolimus tablets will be returned to Novartis for 
destruction. 
 
5.1.5 Toxicity 
Adverse events most frequently observed with Everolimus are rash, stomatitis/oral mucositis, 
fatigue, headache, anorexia, nausea, vomiting, and diarrhea. Infections have not been notably 
frequent or severe. Non-infectious pneumonitis has also been observed. The majority of these AEs 
have been of mild to moderate severity (CTC grade 1-2). Overall, the most frequently observed 
laboratory abnormalities include reduced blood counts, hyperglycemia and hyperlipidemia mostly 
reported as hypercholesterolemia and/or hypertriglyceridemia. 
 
Other less common adverse events include respiratory, thoracic and mediastinal disorders such as 
dyspnea, pleural effusions, cough, hemoptysis and acute respiratory failure; general disorders such 
as fever, general health deterioration, creatinine increase, hypercalcemia and chest pain; 
musculoskeletal and connective tissue disorders such as back pain, pathologic fractures and bone 
pain; and psychiatric disorders such as confusional state. 
 
5.2 Gemcitabine (GEMZAR®) 
 
 
5.2.1 Investigational Drug Description 
Gemcitabine is a pyrimidine analogue of deoxycytidine in which the deoxyribose moiety contains 2 
fluorine atoms at the 2’position. The drug acts as an inhibitor to ribonucleotide reductase and 
 
Amended: 1/11/11 

Page 23 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
inhibition of DNA synthesis may result in perturbations of deoxynucleotide pools and interference 
with DNA chain elongation. The drug is cell-cycle specific and blocks cells in the G1/S interface. 
Cytotoxicity is schedule dependent and increases with increasing duration of exposure. The drug is 
rapidly eliminated from plasma, owing mainly to deamination. Renal clearance of drug is less than 
10% of parent drug. 
 
 
5.2.2 Availability 
The drug is supplied as either a 200 mg or 1 gram lyophilized powder in a 50mL sterile single vial for 
reconstitution. 
 
5.2.3 Administration 
The drug is administered via a freely running intravenous catheter per institutional guidelines. 
 
 
5.2.4 Toxicity 
Toxicities include nausea, vomiting, alopecia, stomatitis, anorexia, fatigue, elevations of hepatic 
transaminases, rash, flu-like symptoms, edema, constipation, paresthesias, hypersensitivity 
reactions, phlebitis, proteinuria, hematuria, reversible myelosuppression, rarely interstitial 
pneumonitis and ARDS and rarely kidney damage. 
 
 
6.0CRITERIA FOR SUBJECT ELIGIBILITY 
 
6.1Subject Inclusion Criteria 
 
• 
Patients must have BCG refractory TisN0M0. BCG-refractory disease is defined as: 
• Patient positive for Cis after 2 consecutive BCG installations 
• OR, patient had a BCG response and failure within 6 months 
• OR, Cis on maintenance BCG 
• 
Pathologic confirmation of urothelial carcinoma by the Department of Pathology at MSKCC 
• 
Karnofsky Performance Status (KPS) >70% 
• 
Age ≥ 18 years 
• 
Adequate bone marrow function as shown by: 
• ANC ≥ 1.5 x 109/L 
• Platelets ≥ 100 x 109/L 
• Hb >9 g/dL 
• 
Adequate liver function as shown by: 
• serum bilirubin ≤ 1.5 x ULN (upper limit of normal) 
• ALT and AST ≤ 2.5x ULN 
• International normalized ratio (INR) ≤1.5 x ULN. (Anticoagulation is allowed if target INR ≤ 1.5 x 
ULN on a stable dose of warfarin or on a stable dose of low molecular weight (LMW) heparin for 
>2 weeks) 
 
• Adequate renal function: serum creatinine ≤ 1.5 x ULN 
Amended: 1/11/11 

Page 24 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
• Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L AND fasting triglycerides ≤ 2.5 x ULN. 
NOTE: In case one or both of these thresholds are exceeded, the patient can only be included 
after initiation of appropriate lipid-lowering medication. After lipid-lowering therapy, patients must 
meet the same criteria, i.e. a fasting serum cholesterol < 300 mg/dL OR < 7.75 mmol/L AND 
fasting triglycerides < 2.5 x ULN, to be eligible for study treatment. 
• Pre-treatment tumor tissue (minimum 10 slides) or 1 paraffin-embedded block available for 
analysis of m-TOR pathway markers. 
• Testing for hepatitis B viral load and serological markers (HBV-DNA, HBsAg, HBsAb, and 
HBcAb) for the following patients: 
 
• All patients who currently live in (or have lived in) Asia, Africa, Central and South America, 
Eastern Europe, Spain, Portugal, or Greece 
 
• Patients with any of the following risk factors: 
 
• Known or suspected past hepatitis B infection 
 
• Blood transfusion(s) prior to 1990 
 
• Current or prior IV drug users 
 
• Current or prior dialysis 
• Household contact with hepatitis B infected person(s) 
• Current or prior high-risk sexual activity 
• Body piercing or tattoos 
• Mother known to have hepatitis B 
• History suggestive of hepatitis B infection, e.g. dark urine, jaundice, or right upper quadrant 
pain 
• Additional patients at the discretion of the investigator 
• Testing for hepatitis C infection (using quantitative RNA-PCR) for patients with any of the 
following risk factors: 
• Known or suspected past hepatitis C infection (including patients with past interferon 
“curative” treatment) 
• Blood transfusion(s) prior to 1990 
• Current or prior IV drug users 
• Household contact of hepatitis C infected person(s) 
• Current or prior high-risk sexual activity 
• Body piercing or tattoos 
• Additional patients at the discretion of the investigator 
 
 
6.2Subject Exclusion Criteria 
 
 
 
 
 
Amended: 1/11/11 

Page 25 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
• 
Patients currently receiving anticancer therapies or who have received anticancer therapies 
within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody 
based therapy, etc.) 
• 
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of 
study drug, patients who have not recovered from the side effects of any major surgery (defined 
as requiring general anesthesia) or patients that may require major surgery during the course of 
the study 
• 
Prior treatment with any investigational drug within the preceding 4 weeks 
 
• 
Patients receiving chronic, systemic treatment with corticosteroids or another 
immunosuppressive agent. Topical or inhaled corticosteroids are allowed. 
• 
Patients should not receive immunization with attenuated live vaccines within 1 week of study 
entry or during study period 
• 
Other malignancies within the past 3 years, except for adequately treated carcinoma of the 
cervix, basal or squamous cell carcinomas of the skin, or adenocarcinoma of the prostate that 
has been surgically treated with a post-treatment PSA that is non-detectable. 
• 
Patients who have any severe and/or uncontrolled medical conditions or other conditions that 
could affect their participation in the study such as: 
• 
symptomatic congestive heart failure of New York Heart Association Class III or IV 
 
• 
unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction 
within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia, or any 
other clinically significant cardiac disease 
• 
Severely impaired lung function as defined by spirometry and diffusing capacity of lung for 
carbon monoxide (DLCO) that is 50% of the normal predicted value and/or 02 saturation that is 
88% or less at rest on room air 
 
• 
Uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN 
 
• 
Active (acute or chronic) or uncontrolled severe infections, including urinary tract infections 
 
• 
Liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis 
 
• 
A known history of HIV seropositivity 
 
• 
Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the 
absorption of Everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, 
malabsorption syndrome, or small-bowel resection) 
• 
Patients with an active, bleeding diathesis 
 
• 
Female patients who are pregnant or breast feeding. Women of childbearing potential must have 
a negative serum pregnancy test within 7 days prior to administration of Everolimus. 
• 
Adults of reproductive potential who are not using effective birth control methods. If barrier 
contraceptives are being used, these must be continued throughout the trial by both sexes. 
Hormonal contraceptives are not acceptable as a sole method of contraception. Patients who 
have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, Everolimus) 
 
 
Amended: 1/11/11 

Page 26 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
• 
Patients with a known hypersensitivity to Everolimus or other rapamycins (sirolimus, 
temsirolimus) or to its excipients 
• 
History of noncompliance to medical regimens 
 
• 
Patients unwilling to or unable to comply with the protocol 
 
• 
Prior radiation to the pelvis 
 
 
 
7.0RECRUITMENT PLAN 
 
Patients will be recruited from the outpatient clinics of the Urology and Genitourinary Oncology 
Services at Memorial Sloan-Kettering Cancer Center (MSKCC). Potential research subjects will be 
identified by a member of the patient’s treatment team, the protocol investigator, or the research 
team. If the investigator is a member of the treatment team, s/he will screen their patient’s medical 
records for suitable research study participants and discuss the study and their potential for enrolling 
in the research study. Potential subjects contacted by their treating physician will be referred to the 
investigator/research staff of the study. The patient’s initial conversation with the investigator/research 
staff and portions of the patient’s MSKCC medical records will be used to confirm that the patient is 
eligible for study participation. 
 
8.0PRETREATMENT EVALUATION 
 
Within 7 days of starting treatment: 
 
• Pregnancy test: Adequate contraception must be used while on study and for 8 weeks after 
last dose of study drug 
 
Within 14 days of starting treatment: 
 
• Hematology 
 
o Complete Blood Count including: hemoglobin, hematocrit, platelets, total white blood 
cell count (WBC) and differential. 
o PT (INR) evaluation will be included for baseline evaluations. 
 
• Blood chemistry 
 
o Comprehensive Metabolic Panel including: sodium, potassium, chloride, bicarbonate, 
calcium, glucose, creatinine, blood urea nitrogen, albumin, total protein, SGOT (AST), 
SGPT (ALT), total bilirubin, alkaline phosphatase, 
o Uric acid, 
o Phosphorus, 
o Serum lipid profile (triglycerides, total cholesterol, HDL, and LDL). 
o Because accurate serum glucose and lipid measurements are required, 
patients should be fasting at the time of the blood sampling. 
 
 
 
Amended: 1/11/11 

Page 27 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
• Urinalysis 
 
o Standard urinalysis. This must be supplemented with laboratory quantification of any 
potentially relevant abnormalities. 
 
• Vital signs 
 
o Vital sign assessment consists of height (first visit), pulse, blood pressure, respiration 
rate, temperature, and weight. Blood pressure, pulse, and respiration rate should be 
measured on patients after at least 3 minutes in the sitting position. 
 
• History and Physical examination 
 
o Physical examination will be performed, which must comprise a total body 
examination (general appearance, skin, neck, eyes, ears, nose, throat, lungs, heart, 
abdomen, back, lymph nodes, extremities, and basic nervous system). 
o Significant findings made after the start of study drug that meet the definition of an 
Adverse Event must be recorded. 
 
• Performance status 
 
o Karnofsky Performance Status (KPS) >70% 
 
 
 
Within 30 days of starting treatment: 
 
• Chest X-Ray 
• Pulmonary function tests 
• Cystoscopy 
• Transurethral Resection 
• ECG:A standard 12-lead ECG is to be performed during screening and significant findings 
must be recorded. 
• HBV testing 
o Hepatitis B testing (HBV-DNA, HBsAg, HBsAb, and HBcAb) for all patients who meet 
the hepatitis B risk criteria outlined in Section 6.1. 
o HBV DNA monitoring should be done depending on the results from serologic 
markers and viral load as listed in Table 9.3-3. 
 
• HCV testing 
 
o Hepatitis C testing (Quantitative RNS-PCR) for all patients who meet the hepatitis C 
risk criteria outlined in Section 6.1. 
o Follow-up testing will be performed, as per the visit schedule, only if the patient has a 
history or is positive at baseline, or both. 
 
 
 
 
9.0TREATMENT/INTERVENTION PLAN 
Amended: 1/11/11 

Page 28 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
9.1 Phase I Schedule and Dose Administration 
 
Table 9.1-1 Treatment Drug Dose and Schedule 
Dose level 
Everolimus Dose and schedule 
Gemcitabine Dose and Schedule 
1 (starting dose) 
5 mg every other day 
2000 mg tw ice w eekly 
2 
5 mg daily 
2000 mg tw ice w eekly 
3 
10mg daily 
2000 mg tw ice w eekly 
 
All chemotherapy will be administered in the outpatient chemotherapy unit. 
 
 
9.1.1 Dose Escalation Scheme 
 
3 dose levels of continuous Everolimus (Everolimus dose levels: Dose level 1: 5 mg every other day, 
Dose level 2: 5 mg daily, and Dose level 3: 10 mg daily) in combination with a fixed dose of 
intravesical gemcitabine at a dose of 2000 mg twice weekly for 3 weeks followed by a week of rest 
from gemcitabine (there is no rest week from Everolimus), and a second course of intravesical 
gemcitabine followed by a week of rest from gemcitabine will be evaluated using the DLT rules 
outlined below: 
 
 
 
 
 
Number of subjects with 
DLT 
Action 
0 of 3 subjects 
Escalate to next highest dose level and enroll 
up to 3 subjects 
1 of 3 subjects 
Enroll up to 3 more subjects at the same dose 
level 
1 of 6 subjects 
Escalate to next highest dose level and enroll 
up to 3 more subjects 
2 or 3 subjects in the first 3 
subjects 
De-escalate to lower dose level and enroll up to 
6 subjects 
≥ 2 of 6 subjects 
De-escalate to lower dose level and enroll up to 
6 subjects 
 
If 2 of the first 2 subjects have DLT, the enrollment of a third subject at the same dose level is not 
necessary. Similarly, if 2 of 4 subjects or 2 of 5 subjects have DLT, it is not necessary to enroll 
subsequent subjects at the same dose level. 
 
 
There will be no planned dose level below dose level 1. If ≥ 2 DLTs occur at dose level 1, then the 
study will be terminated. 
 
There will be no planned dose level beyond dose level 3. If no DLTs occur at dose level 3, the 
Phase II portion of the trial will be initiated. 
Amended: 1/11/11 

Page 29 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
 
Patients will be assessed for DLTs up the completion of the 3rd cycle of treatment. 
 
9.1.2 Maximum Tolerated Dose 
 
The MTD is the dose level at which no more than 1 out of 6 patients experience DLT. 
If ≥ 2 subjects at the first dose level experience DLT, then the study will be terminated and the 
combination of Everolimus at a dose of 5 mg every other day with intravesical gemcitabine at a dose 
of 2000 mg twice weekly will be considered unsafe in this population. 
 
Patients will be observed for DLTs through one cycle of treatment (4 weeks) prior to dose escalation 
for the next dose level. No intrapatient dose escalation will occur. DLTs will be defined as follows, 
using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: 
 
1) Any evidence of grade 3 or 4 toxicity under Renal and Urinary Disorders in CTCAE version 4.0. 
 
2)  Febrile neutropenia (absolute neutrophil count (ANC)) < 1000/μL plus oral temperature to 8.5°C) 
 
3)  Grade 4 neutropenia (ANC <500/μL) for ≥ 7 days 
 
4)  Other grade 4 hematologic toxicity 
 
5)  Other nonhematologic grade 3 or 4 treatment-related toxicity, excluding nausea/vomiting, rash, 
untreated hyperlipidemia or grade 3 fatigue lasting ≤ 7 days. 
 
6)  Any nonhematologic toxicity requiring treatment delay for > 7 days during cycle 1. 
 
 
 
9.2 Phase II Dose Administration 
 
The dose level of Everolimus for the Phase II Study will be based on the MTD from Phase I part of 
the study, administered continuously, and intravesical gemcitabine will be administered at a dose of 
2000 mg twice weekly for 3 weeks, followed by a week of rest and a second course of intravesical 
gemcitabine, followed by a week of rest (there is no rest week for Everolimus, only for gemcitabine). 
Everolimus will be continued for 12 months in the patients who achieve a CR after two courses of 
gemcitabine. Patients demonstrating a CR (by cystoscopy and cytology) will be observed with serial 
cystoscopies every 3 months. 
 
All chemotherapy will be administered in the outpatient chemotherapy unit.9.2.1 Interruption or 
Discontinuation of Treatment During Phase II 
 
For patients who are unable to tolerate the protocol-specified dosing schedule, dose adjustments of 
Everolimus, but not of gemcitabine, are permitted. If administration of Everolimus must be 
interrupted because of unacceptable toxicity, drug dosing will be interrupted or modified according to 
rules described in Section 9.1. Toxicity will be assessed using the NIH-NCI CTCAE, version 4.0 
(http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). 
If at any point a patient develops any grade 3 toxicity suspected to be related to gemcitabine, 
gemcitabine may be delayed for up to 14 days while Everolimus will continue to be taken 
continuously. If at any point a patient develops any grade 4 toxicity suspected to be related to 
 
Amended: 1/11/11 

Page 30 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
gemcitabine, the patient will be taken off study. If a dose delay of gemcitabine greater than 14 is 
 
 
Nonhematological toxicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
required, the patient will be taken off study. 
 
Patients who are removed from study due to withdrawal of consent, lost to follow-up, or 
administrative problems should not be considered unevaluable and will be replaced. 
 
 
9.3 Phase II Dose Modifications 
 
There will be no dose modifications for gemcitabine, only for Everolimus. 
 
 
Table 9.3-1 Phase II Everolimus Dose Modifications 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended: 1/11/11 

Page 31 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
Grade 2 
(except pneumonitis – refer to Section 4.2) 
Grade 3 
(except hyperlipidemia*) 
(except pneumonitis – refer to Section 4.2) 
Grade 4 
If the toxicity is tolerable to the patient, maintain the same 
dose. If the toxicity is intolerable to patient, interrupt 
Everolimus until recovery to grade ≤1. Then reintroduce 
Everolimus at same dose. 
If event returns to grade 2, then interrupt Everolimus until 
recovery to grade ≤1. Then reintroduce Everolimus at the 
low er dose level. 
Interrupt Everolimus until recovery to grade ≤1. Then 
reintroduce Everolimus at the low er dose level. For 
pneumonitis, consider the use of a short course of 
corticosteroids. 
Discontinue Everolimus. 
Hematological toxicity 
Grade 2 Thrombocytopenia (platelets <75, ≥50x109/L) 
Grade 3 Thrombocytopenia (platelets <50, ≥ 25 x109/L) 
Grade 4 Thrombocytopenia (platelets <25 x109/L) 
Grade 3 Neutropenia (neutrophils <1, ≥0.5 x109/L) 
Grade 4 Neutropenia (neutrophils <0.5 x109/L) 
Grade 3 febrile neutropenia (not life-threatening) 
Grade 4 febrile neutropenia (life-threatening) 
Interrupt Everolimus until recovery to grade ≤1 (>75 x109/L). 
Then reintroduce Everolimus at initial dose. 
If thrombocytopenia returns to grade 2, interrupt Everolimus 
until recovery to grade ≤1. Then reintroduce Everolimus at 
the low er dose level. 
Interrupt Everolimus until recovery to grade ≤1 (platelets ≥ 
75 x109/L). Then resume Everolimus at one dose level 
low er. If grade 3 thrombocytopenia recurs, discontinue 
Everolimus 
Discontinue Everolimus. 
Interrupt Everolimus until recovery to grade ≤1 (neutrophils 
≥1.5 x 109/L). Then resume Everolimus at the initial dose. If  
ANC returns to grade 3, hold Everolimus until the ANC ≥1.5 
x 109/L. Then resume Everolimus dosing at the low er dose 
level. Discontinue patient from study therapy for a third 
episode of grade 3 neutropenia. 
Interrupt Everolimus until recovery to grade ≤1 (neutrophils 
≥1.5 x 109/L). Then resume Everolimus at the low er dose 
level. If grade 3 or grade 4 neutropenia occurs despite this 
dose reduction, discontinue Everolimus. 
Interrupt Everolimus until resolution of fever and neutropenia 
to grade ≤1. Hold further Everolimus until the A NC 
≥1,500/mm3 and fever has resolved. Then resume 
Everolimus at the low er dose level. If febrile neutropenia 
recurs, discontinue Everolimus. 
Discontinue Everolimus. 
Any hematological or nonhematological toxicity 
requiring interruption for ≥ 3 weeks 
Discontinue Everolimus 
 
 
*Grade 3 hyperlipidemia (hypercholesterolemia and/or hypertriglyceridemia) should be managed 
using medical therapies 
 
All interruptions or changes to study drug administration must be recorded. 
 
 
 
9.3.1 Monitoring of Everolimus Suspected Toxicities 
 
 
Amended: 1/11/11 

Page 32 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
Patients whose treatment is interrupted or permanently discontinued due to an adverse event or 
abnormal laboratory value suspected to be related to Everolimus must be followed at least weekly 
until the adverse event or abnormal laboratory resolves or returns to grade 1. If a patient requires a 
dose delay of >21 days from the intended day of the next scheduled dose, then the patient must be 
discontinued from the study. 
 
9.3.2 Management of Stomatitis/Oral Mucositis/Mouth Ulcers 
Stomatitis/oral mucositis/mouth ulcers due to Everolimus should be treated using local supportive 
care. Please note that investigators in earlier trials have described the oral toxicities associated with 
Everolimus as mouth ulcers, rather than mucositis or stomatitis. If your examination reveals mouth 
ulcers rather than a more general inflammation of the mouth, please classify the adverse event as 
such. Please follow the paradigm below for treatment of stomatitis/oral mucositis/mouth ulcers: 
 
1.  For mild toxicity (grade 1), use conservative measures such as non-alcoholic mouth wash or 
salt water (0.9%) mouth wash several times a day until resolution. 
2.  For more severe toxicity, (such as grade 2, in which case patients have pain but are able to 
maintain adequate oral alimentation, or grade 3, in which case patients cannot maintain 
adequate oral alimentation), the suggested treatments are topical analgesic mouth treatments 
(i.e., local anesthetics such as benzocaine, butyl aminobenzoate, tetracaine 
hydrochloride, menthol, or phenol) with or without topical corticosteroids, such as 
triamcinolone oral paste 0.1% (Kenalog in Orabase®). 
3.  Agents containing hydrogen peroxide, iodine, and thyme derivatives may tend to worsen mouth 
ulcers. It is preferable to avoid these agents. 
4.  Antifungal agents must be avoided unless a fungal infection is diagnosed. In particular, systemic 
imidazole antifungal agents (ketoconazole, fluconazole, itraconazole, etc.) should be avoided in 
all patients due to their strong inhibition of Everolimus metabolism, thereby leading to higher 
Everolimus exposures. Therefore, topical antifungal agents are preferred if an infection is 
diagnosed. Similarly, antiviral agents such as acyclovir should be avoided unless a viral infection 
is diagnosed. 
Note: Stomatitis/oral mucositis should be appropriately graded using the functional grading given on 
the NCI-CTCAE, version 4.0. 
 
9.3.3 Management of Hyperlipidemia and Hyperglycemia 
 
 
Treatment of hyperlipidemia should take into account the pretreatment status and dietary habits. 
Blood tests to monitor hyperlipidemia must be taken in the fasting state. Grade 2 
hypercholesterolemia (>300 mg/dL or 7.75 mmol/L) or grade 2 hypertriglyceridemia (>2.5 x ULN) 
should be treated with a 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitor (e.g., 
atorvastatin, pravastatin) or appropriate lipid-lowering medication, in addition to diet. Patients should 
be monitored clinically and through serum biochemistry for the development of rhabdomyolysis and 
other adverse events as required in the product label/data sheets for HMG-CoA reductase inhibitors. 
 
 
 
Amended: 1/11/11 

Page 33 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
Note: Concomitant therapy with fibrates and an HMG-CoA reductase inhibitor is associated with an 
increased risk of a rare but serious skeletal muscle toxicity manifested by rhabdomyolysis, markedly 
elevated creatine kinase (CPK) levels and myoglobinuria, acute renal failure, and, sometimes, 
death. The risk versus benefit of using this therapy should be determined for individual patients 
based on their risk of cardiovascular complications of hyperlipidemia. 
 
Grade 3 hyperglycemia has been observed in patients receiving Everolimus therapy. In many cases 
in study Everolimus C2222, the affected patients had an abnormal fasting glucose at baseline. 
Monitoring of fasting serum glucose is recommended prior to the start of everolimus therapy and 
periodically thereafter. Based on this finding, it is suggested that optimal glucose control should be 
achieved before starting a patient on Everolimus and should be monitored during Everoli mus 
therapy. 
 
 
 
9.3.4 Management of non-infectious pneumonitis 
 
Both asymptomatic radiological changes (grade 1) and symptomatic noninfectious pneumonitis 
(grade 2 = not interfering with activities of daily living, or grade 3 = interfering with activities of daily 
living and oxygen indicated) have been noted in patients receiving Everolimus therapy. 
Noninfectious pneumonitis has been associated with Everolimus and other mTOR inhibitors.(40) In 
order to monitor for asymptomatic (grade 1) pulmonary infiltrates, a chest X-ray is required if a CT 
scan of chest is not used for bimonthly disease evaluations. Additional chest CT scans may be 
performed, when clinically necessary. If noninfectious pneumonitis develops, a consultation with a 
pulmonologist should be considered. If the patient develops grade 3 pneumonitis, treatment with 
Everolimus should be interrupted and the patient should be treated as medically indicated (short 
course corticosteroids, oxygen, etc.). 
Management of noninfectious pneumonitis suspected to be associated with Everolimus and dose 
modifications instructions are provided below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended: 1/11/11 

Page 34 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
Table 9.3-2 Management of Non-Infectious Pneumonitis 
 
Worst Grade 
Pneumonitis 
Required Investigations 
Management of 
Pneumonitis 
Everolimus Dose Adjustment 
Grade 1 
CT scans w ith lung w indows and 
pulmonary function testing 
including: spirometry, DLCO, and 
room air O2 saturation at rest. 
Repeat chest x-ray/CT scan 
every 2 cycles until return to 
baseline. 
No specific therapy is 
required 
Administer 100% of Everolimus dose. 
Grade 2 
CT scan w ith lung w indow s and 
pulmonary function testing 
including: spirometry, DLCO, and 
room air O2 saturation at rest. 
Repeat each subsequent cycle 
until return to baseline. Consider 
bronchoscopy * 
Symptomatic only. 
Prescribe 
corticosteroids if 
cough is 
troublesome. 
Reduce Everolimus dose until recovery t o 
≤ grade 1. Everolimus may also be 
interrupted if symptoms are troublesome. 
Patients w ill be w ithdraw n from the study 
if they fail to recover to ≤ grade 1 w ithin 3 
weeks. 
Grade 3 
CT scan w ith lung w indow s and 
pulmonary function testing 
including: spirometry, DLCO, and 
room air O2 saturation at rest. 
Repeat each subsequent cycle 
until return to baseline. 
Bronchoscopy is recommended * 
Prescribe 
corticosteroids if 
infective origin is 
ruled out. Taper as 
medically indicated. 
Hold Everolimus until recovery to ≤ 
grade 1. May restart protocol treatment 
within 2 w eeks at a reduced dose (by 
one level) if evidence of clinical benefit. 
Patients w ill be w ithdraw n from the study 
if they fail to recover to ≤ grade 1 w ithin 2  
weeks. 
Grade 4 
CT scan w ith lung w indow s and 
required pulmonary function 
testing includes: spirometry, 
DLCO, and room air O2 saturation 
at rest. Repeat each subsequent 
cycle until return to baseline. 
Bronchoscopy is recommended *. 
Prescribe 
corticosteroids if 
infective origin is 
ruled out. Taper as 
medically indicated. 
Discontinue Everolimus. 
*A bronchoscopy w ith biopsy and/or bronchoalveolar lavage is recommended. 
 
 
Management of hepatitis reactivation 
 
9.3.5 Management of Hepatitis B 
 
Table 9.3-3 provides details of monitoring and prophylactic therapy according to the baseline results 
of viral load and serologic markers testing. 
 
 
Table 9.3-3 Action to be taken for Positive Baseline Hepatitis B Results 
Test 
Result 
Result 
Result 
Result 
Result 
HBV-DNA  
+ 
+ or - 
- 
- 
- 
HBsAg 
+ or - 
+ 
- 
- 
- 
HBs Ab 
+ or - 
+ or - 
+ 
and no prior HBV 
vaccination 
+ or - 
- 
or + w ith prior HBV  
vaccination 
HBc Ab 
+ or - 
+ or - 
+ or - 
+ 
- 
Recommendation 
Prophylaxis treatment should 
be started 1-2 w eeks prior to 
No prophylaxis 
No specific action 
 
Amended: 1/11/11 

Page 35 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
Test 
Result 
Result 
Result 
Result 
Result 
first dose of study drug 
Monitor HBV-DNA 
approximately every 4-8 
weeks 
Monitor HBV-DNA approximately 
every 3-4 w eeks 
 
 
In cancer patients with hepatitis B, whether carriers or in chronic state, use of antivirals during 
anticancer therapy has been shown to reduce the risk of hepatitis B virus (HBV) reactivation and 
associated HBV morbidity and mortality.(41) 
 
Antiviral prophylaxis therapy should continue for at least 4 weeks after last dose of study drug. 
 
For hepatitis B reactivation, definition, and management guidelines, see Table 9.3-4 Guidelines for 
management of hepatitis B. 
 
Table 9.3-4 Guidelines for Management of Hepatitis B 
 
HBV reactivation (with or without clinical signs and symptoms)* 
For patients w ith baseline 
results: 
Positive HBV-DNA 
OR 
positive HBsAg 
-------------------------------------- 
reactivation is defined as: 
[Increase of 1 log in HBV-DNA  
relative to baseline HBV-DNA  
value OR new  appearance of 
measurable HBV-DNA] 
AND 
ALT elevation x 5 ULN 
Treat: Start a second antiviral 
AND 
Interrupt study drug administration until resolution: 
• 
≤ grade 1 ALT (or baseline ALT, if > grade 1) and 
• 
≤ baseline HBV-DNA levels 
If resolution occurs w ithin ≤ 28 days study drug should be re-started at 
one dose low er, if available. (see Table 9.1-1 – Treatment Drug Dose 
and Schedule) If the patient is already receiving the low est dose of study 
drug according to the protocol, the patient should restart at the same 
dose after resolution. Both antiviral therapies should continue at least 4 
weeks after last dose of study drug. 
If resolution occurs > 28 days Patients should discontinue study drug but  
continue both antiviral therapies at least 4 w eeks after last dose of study 
drug. 
For patients w ith baseline 
results: 
Negative HBV-DNA and HBsAg 
AND 
[Positive HBs Ab (w ith no prior 
history of vaccination against 
HBV), OR positive HBc Ab] 
------------------------------------- 
reactivation is defined as: 
New  appearance of 
measurable HBV-DNA  
Treat : Start first antiviral medication 
AND 
Interrupt study drug administration until resolution: 
• 
≤ baseline HBV-DNA levels 
If resolution occurs w ithin ≤ 28 days study drug should be re-started at 
one dose low er, if available. (see Table 9.1-1 – Treatment Drug Dose 
and Schedule) If the patient is already receiving the low est dose of study 
drug according to the protocol, the patient should restart at the same 
dose after resolution. Antiviral therapy should continue at least 4 w eeks 
after last dose of study drug. 
If resolution occurs > 28 days Patients should discontinue study drug but 
continue antiviral therapy at least 4 w eeks after last dose of study drug. 
* All reactivations of hepatitis B are to be recorded as grade 3 (CTCAE v 3.0 Metabolic Laboratory/Other: Viral 
Re-activation), unless considered life threatening by the investigator; in which case they should be recorded as 
grade 4 (CTCAE v 3.0 Metabolic Laboratory/Other: Viral Re-activation). Date of viral reactivation is the date on 
which both DNA and ALT criteria were met (e.g. for a patient who was HBV-DNA positive on 01-JAN-10 and 
whose ALT reached ≥ 5 × ULN on 01-APR-10, the date of viral reactivation is 01-APR-10). 
 
9.3.6 Monitoring for Hepatitis C 
Amended: 1/11/11 

Page 36 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
The following two categories of patients should be monitored every 4–8 weeks for HCV reactivation: 
 
• 
Patients with detectable HCV RNA-PCR test at baseline. 
 
• 
Patients known to have a history of HCV infection, despite a negative viral load test at baseline 
(including those that were treated and are considered ‘cured’) 
 
For definition of hepatitis C reactivation and the management guidelines, see Table 9.3-5. 
Guidelines for management of hepatitis C. 
 
Table 9.3-5 Guidelines for management of hepatitis C 
 
HCV reactivation* 
For patients w ith baseline results: 
Detectable HCV-RNA, 
reactivation is defined as: 
ALT elevation x 5 ULN 
Discontinue study drug 
For patients w ith baseline results: 
Know ledge of past hepatitis C infection w ith no detectable HCV-RNA, 
reactivation is defined as: 
New  appearance of detectable HCV-RNA 
Discontinue study drug 
* All reactivations of hepatitis C are to be recorded as grade 3 (CTCAE v 3.0 Metabolic Laboratory/Other: Viral 
Re-activation), unless considered life threatening by the investigator; in which case they should be recorded as 
grade 4 (CTCAE v 3.0 Metabolic Laboratory/Other: Viral Re-activation). 
 
 
9.4 Concomitant therapy 
 
Patients will be instructed not to take any additional medications (including over-the-counter products) 
during the course of the study without prior consultation with the investigator. At each visit, the 
investigator will ask the patient about any new medications he/she is or has taken after the start of the 
study drug. 
 
All Concomitant medications/Significant non-drug therapies taken ≤30 days prior to start and after 
start of study drug, including physical therapy and blood transfusions, should be recorded. 
 
The following restrictions apply during the entire duration of the study: 
 
• 
No other investigational therapy should be given to patients. 
 
• 
No anticancer agents other than the study medication should be given to patients. If such agents 
are required for a patient, then the patient must first be withdrawn from the study. 
• 
Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir) or 
P-gp should be avoided 
 
• 
Seville orange, star fruit, grapefruit, and their juices affect P450 and P-gp activity. Concomitant 
use should be avoided 
• 
Co-administration with moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole) or P-gp 
inhibitors should be used with caution. If patient requires co-administration of moderate CYP3A4 
Amended: 1/11/11 

Page 37 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
inhibitors or P-gp inhibitors, reduce the dose of Everolimus to half the currently used dose. 
Additional dose reductions to every other day may be required to manage toxicities. If the 
inhibitor is discontinued, the Everolimus dose should be returned to the dose used prior to 
initiation of the moderate CYP3A4/P-gp inhibitor. 
• 
Avoid the use of strong CYP3A4 inducers. 
 
• 
No chronic treatment with systemic steroids or other immunosuppressive agents (at a dose 
equivalent or greater than 20 mg prednisone per day). Topical or inhaled corticosteroids are 
allowed. 
• 
Everolimus may affect the response to vaccinations, making the response to the vaccination less 
effective. Live vaccines should be avoided while a patient is treated with Everolimus. 
 
• 
Oral anticoagulants such as warfarin are CYP2C9 substrates and, as such, no interaction with 
Everolimus is expected. However, drug-drug interaction studies between macrolide antibiotics 
and warfarin have produced mixed outcomes and the disparity in these findings has led to the 
conclusion that multiple factors may alter the clearance of warfarin. The co-administration of 
Everolimus and oral anticoagulants is possible but should be subject to verification of 
coagulation (INR) once steady state is reached (after one week’s treatment). 
 
A comprehensive list of cytochrome P450 isoenzymes and CYP3A4 inhibitors, inducers, and 
substrates can be found at http://medicine.iupui.edu/flockhart. This website is continually revised 
and should be checked frequently for updates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended: 1/11/11 

Page 38 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
Table 9.4-1 Clinically Relevant Drug Interaction: Substrates, Inducers, and Inhibitors of 
Isoenzyme CYP3A4. 
 
SUBSTRATES 
Antibiotics: 
Clarithromycin, erythromycin, telithromycin 
Calcium channel blockers: 
Amlodipine, diltiazem, felodipine, lercanidipine, 
nifedipine, nisoldipine, nitrendipine, verapamil 
Anti-arrhythmics: 
Quinidine 
HMG CoA reductase inhibitors: 
Cerivastatin, lovastatin, simvastatin 
Benzodiazepines: 
Alprazolam, diazepam, midazolam, triazolam 
Steroid 6beta-OH: 
estradiol, hydrocortisone, progesterone, testosterone 
Immune modulators: 
Cyclosporine, tacrolimus (FK506) 
Miscellaneous: 
Alfentanil, aprepitant, aripirazole, buspirone, cafergot, 
caffeine, cilostazol, cocaine, codeine-N-demethylation, 
dapsone, dexamethasone, dextromethorphan, 
docetaxel domperidone, eplerenone, fentanyl, 
finasteride, Gleevec/imatinib, haloperidol, irinotecan, 
LAAM, lidocaine, methadone, nateglinide, ondansetron, 
pimozide, propranolol, quetiapine, quinine, risperidone, 
salmeterol, sildenafil, sirolimus, sorafenib, sunitinib, 
tamoxifen, taxol, terfenadine, torisel, trazodone, 
vincristine, zaleplon, ziprasidone, zolpidem 
HIV Antivirals: 
Indinavir, nelfinavir, ritonavir, saquinavir 
Prokinetic: 
Cisapride 
Antihistamines: 
Astemizole, chlorpheniramine, terfenadine 
INDUCERS 
Barbiturates, carbamazepine, glucocorticoids, modafinil, oxcarbazepine, phenobarbital, phenytoin, 
pioglitazone, rifabutin, rifampin, St. John’s wort, troglitazone, efavirenz, nevirapine 
INHIBITORS 
Strong inhibitors: 
indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, 
telithromycin, 
Posaconazole (Krishna et al, 2009) 
Moderate inhibitors: 
aprepitant, diltiazem, erythromycin, fluconazole, grapefruit juice, verapamil, 
Weak inhibitors: 
Cimetidine, 
Seville orange (Malhotra et al, 2001) 
 
Amended: 1/11/11 

Page 39 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
 
Unclassified as per the Indiana University DDI listing: 
 
Ciprofloxacin, delaviridine, troleandamycin, mibefradil, amiodarone, chloramphenicol, 
diethyldithiocarbamate, fluvoxamine, starfruit, gestodene, imatinib, mifepristone, norfloxacin, 
norfluoxetine, voriconazole* 
 
Based on http://medicine.iupui.edu/clinpharm/ddis/table.asp as of December 01, 2009 
*Voriconazole (unclassified as per the Indiana University DDI table) Strong inhibitor according to the 
following reference: (http://www.nature.com/clpt/journal/v80/n5/pdf/clpt2006438a.pdf) 
 
 
 
Table 9.4-2 Clinically Relevant Drug Interactions Mediated by P-gP 
PgP Substrates 
PgP Inhibitors in vivo 
PgP Inducers 
digoxin, 
fexofenadine, indinavir, 
vincristine, colchicine, 
topotecan, paclitaxel 
amiodarone, azithromycin, 
captopril, carvedilol, 
clarithromycin, conivaptan, 
cyclosporine, diltiazem, 
elacridar, erythromycin, 
felodipine, (GF120918), 
itraconazole, ketocoanzole, 
lopinavir, (LY335979), 
mibefradil, nifedipine, 
nitrendipine, (PSC833), 
quinidine, ranolazine, 
ritonavir, talinolol, valspodar, 
verapamil 
rifampin, St John’s wort 
 
 
Reference: 
 
Internal Clinical Pharmacology Drug-drug interaction (DDI) memo, updated Dec. 2, 2009, which 
summarizes  DDI  data  from  three  sources  including  the  FDA’s  “Guidance  for  Industry,  Drug 
Interaction  Studies,  the  University  of  Washington’s  Drug  Interaction  Database,  and  Indiana 
University School of Medicine's Drug Interaction Table." 
 
NOTES:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance 
s/UCM072101.pdf 
 
**This list of clinically relevant drug interactions is updated as of December 02, 2009** 
 
 
10.0EVALUATION DURING TREATMENT/INTERVENTION 
 
 
 
 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 40 of 62 
 
 
 
Phase I Visit Schedule 
*continued on next page* 
Screening 
Pre-Treatment 
Evaluations 
Cycle 1 
(Weeks +2 days) 
Cycle 2 
(Weeks +2 days) 
28-Day Cycles (+7 days) 
Within 
30 Days 
Within 
14 Days 
Within 
7 Days 
1 
2 
3 
41 
5 
6 
7 
81 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Informed Consent 
X 
ECG 
X 
Pulmonary Function 
Tests 
X 
Urine Culture 
X 
Urine Cytology 
X 
X 
X 
X 
X 
Cystoscopy 
X 
X 
X 
X 
X 
Transurethral Resection 
(TUR)4 
X 
Chest X-Ray 
X 
X 
X 
X 
X 
HBV-DNA, HBsAg, HBs Ab, 
HBs Ab, HCV-RNA-PCR2 
X 
HBV DNA, HCV RNA-PCR3 
X 
X 
X 
X 
Karnofsky Performance 
Status 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
Complete History 
X 
Physical Exam 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 41 of 62 
 
 
Phase I Visit Schedule (Cont.) 
Screening 
Pre-Treatment 
Evaluations 
Cycle 1 (Weeks 
+2 days) 
Cycle 2 (Weeks 
+2 days) 
28-Day Cycles (+7 days) 
Within 30 
Days 
Within 
14 Days 
Within 7 
Days 
1 
2 
3 
41 
5 
6 
7 
81 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Vital Signs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Complete Blood Count 
(hemoglobin, hematocrit, 
platelets, total white blood cell 
count (WBC) and differential) 
5
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Comprehensive Panel 
(sodium, potassium, chloride, 
bicarbonate, calcium, glucose, 
creatinine, blood urea nitrogen, 
albumin, total protein, SGOT 
(AST), SGPT (ALT), total 
bilirubin, alkaline phosphatase) 
5 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Uric Acid 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Phosphorus 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum Lipid Profile 
(triglycerides, total cholesterol, 
HDL, and LDL) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum Pregnancy Test 
X 
Collection of Tissue 
Specimen 
X 
Toxicity Assessment 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Gemcitabine 
X 
X 
X 
X 
X 
X 
Everolimus 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 42 of 62 
 
 
11 w eek of rest from gemcitabine. There is no w eek of rest from Everolimus, w hich is taken continuously. 
 
2All patients should be screened for hepatitis risk factors and any past illnesses of hepatitis B and hepatitis C.  It is highly recommended that patients positive HBV-DNA or 
HBsAg are treated prophylactically w ith an antiviral for 1-2 w eeks prior to receiving study drug (see Section 3.2.7). The antiviral treatment should continue throughout the entire 
study period and for at least 4 w eeks after the last dose of study drug. Patients w ith viral hepatitis C risk factors should be screened for HCV RNA-PCR. 
 
3 Patients on antiviral prophylaxis treatment or positive HBV antibodies should be tested for HBV-DNA according to study visit schedule. Patients w ith positive HCV-RNA PCR 
or a history of past infection, even if treated and considered ‘cured’ – should be follow ed by HCV-RNA PCR according to visit schedule. 
 
4During follow -up, if a suspicious or positive cystoscopy/cytology is found, a TUR w ill be performed no later than 4 w eeks. 
 
5All blood w ork w ill be done monthly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 43 of 62 
 
 
 
Phase II Visit Schedule 
*continued on next page* 
Screening 
Pre-Treatment 
Evaluations 
Cycle 1 
(Weeks +2 
days) 
Cycle 2 
(Weeks +2 
days) 
28-Day Cycles (+7 days) 
Within 
30 Days 
Within 
14 Days 
Within 
7 Days 
1 
2 
3 
41 
5 
6 
7 
81 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
15 
18 
21 
24 
Informed Consent 
X 
ECG 
X 
Pulmonary Function Tests 
X 
Urine Culture 
X 
Urine Cytology 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Cystoscopy 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Transurethral Resection 
(TUR)4 
X 
Chest X-Ray 
X 
X 
X 
X 
X 
X 
X 
X 
X 
HBV-DNA, HBsAg, HBs 
Ab, HBs Ab, HCV-RNA- 
PCR2 
X 
HBV DNA, HCV RNA-PCR3 
X 
X 
X 
X 
Karnofsky Performance 
Status 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis 
X 
Complete History 
X 
Physical Exam 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Phase II Visit Schedule (Cont.) 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 44 of 62 
 
 
Screening 
Pre-Treatment Evaluations 
Cycle 1 (Weeks 
+2 days) 
Cycle 2 (Weeks 
+2 days) 
28-Day Cycles (+7 days) 
Within 
30 Days 
Within 
14 Days 
Within 
7 Days 
1 
2 
3 
41 
5 
6 
7 
81 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
15 
18 
21 
24 
Vital Signs 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Complete Blood Count 
(hemoglobin, hematocrit, 
platelets, total white blood 
cell count (WBC) and 
differential) 
5
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Comprehensive Panel 
(sodium, potassium, chloride, 
bicarbonate, calcium, 
glucose, creatinine, blood 
urea nitrogen, albumin, total 
protein, SGOT (AST), SGPT 
(ALT), total bilirubin, alkaline 
phosphatase) 
5
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Uric Acid 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Phosphorus 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum Lipid Profile 
(triglycerides, total 
cholesterol,  HDL, and LDL) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum Pregnancy Test 
X 
Collection of Tissue 
Specimen 
X 
Toxicity Assessment 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Gemcitabine 
X 
X 
X 
X 
X 
X 
Everolimus 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 45 of 62 
 
 
11 w eek of rest from gemcitabine. There is no w eek of rest from Everolimus, w hich is taken continuously. 
 
2All patients should be screened for hepatitis risk factors and any past illnesses of hepatitis B and hepatitis C.  It is highly 
recommended that patients positive HBV-DNA or HBsAg are treated prophylactically w ith an antiviral for 1-2 w eeks prior to 
receiving study drug (see Section 3.2.7). The antiviral treatment should continue throughout the entire study period and for 
at least 4 w eeks after the last dose of study drug. Patients w ith viral hepatitis C risk factors should be screened for HCV 
RNA-PCR. 
 
3 Patients on antiviral prophylaxis treatment or positive HBV antibodies should be tested for HBV-DNA according to study 
visit schedule. Patients w ith positive HCV-RNA PCR or a history of past infection, even if treated and considered ‘cured’ – 
should be follow ed by HCV-RNA PCR according to visit schedule. 
 
4During follow -up, if a suspicious or positive cystoscopy/cytology is found, a TUR w ill be performed no later than 4 w eeks. 
 
5All blood w ork w ill be done monthly the first 12 months, then every three months for one year. 
 
 
 
 
11.0TOXICITIES/SIDE EFFECTS 
 
Known Undesirable Side Effects of Everolimus 
 
Overall, the most frequent adverse effects suspected to be related to Everolimus have been 
stomatitis, rash, anemia, fatigue, asthenia, diarrhea, anorexia, nausea, hypercholesterolemia, 
mucosal inflammation, vomiting, hypertriglyceridemia, cough, peripheral edema, dry skin, epistaxis, 
pruritus, and dyspnea. The most common grade 3 or 4 adverse reactions suspected to be related to 
treatment were anemia, infections, hyperglycemia, stomatitis, fatigue, lymphopenia, 
hypercholesterolemia, pneumonitis, and elevated gamma-glutamyltransferase concentrations. 
 
The principal DLT in Phase 1 trials has been grade 3 stomatitis. 
 
Hyperlipidemia was reported as a serious adverse reaction. It is a recognized side effect of 
rapamycins. Use of lipid-lowering drugs should be associated with dietary recommendations. 
Monitoring of blood lipid levels requires patients to be fasting so that this aspect must be verified 
when interpreting results. 
 
Hyperglycemia was reported as a serious adverse reaction. Similarly, the fasting state of patients 
should be verified when interpreting results. 
 
Pneumonitis is a recognized adverse effect of rapamycins (sirolimus, temsirolimus, and everolimus). 
Numerous case reports in the literature suggest that rapamycin-associated pneumonitis is relatively 
unaggressive, limited in extent, and reversible upon drug discontinuation. The term ‘pneumonitis’ is 
used here to describe noninfectious, nonmalignant infiltration in the lungs, which is evident 
radiologically. More precise diagnosis should follow histocytological examination following lung 
biopsy, generally during bronchoscopy that may or may not be symptomatic. 
 
In oncology studies with Everolimus, severe pneumonitis suspected as drug-related has been 
reported as a serious adverse event on 13 occasions and additionally in the following associated 
preferred terms, including acute respiratory distress syndrome (n=2), alveolitis (n=1) and allergic 
alveolitis (n=1), interstitial lung disease (n=10), lung infiltration (n=23), cryptogenic organizing 
pneumonia, lung consolidation, pulmonary alveolar hemorrhage, pulmonary toxicity, and pulmonary 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 46 of 62 
 
 
fibrosis (n=1, each). One fatal case of drug-related pneumonitis was reported for a patient with 
metastatic infiltrating ductal carcinoma of the breast treated with 10 mg/day, which developed 
approximately 2 months after starting Everolimus. Cytologies for both the pleural and pericardial fluids 
were positive for malignancy. The death was considered possibly related to the underlying late stage 
tumor and study drug. Additionally, 1 patient treated with 10 mg/day died due to severe acute 
respiratory distress syndrome and septic shock. Thoracic computed tomography (CT) scan 
demonstrated condensation in the majority of the left lower lobe and frosted glass appearance in the 
left upper lobe, lingula, and right lung. 
 
Along with the cases of noninfectious pneumonitis, serious opportunistic infections have also been 
reported in cancer patients treated with Everolimus: mycobacterium, aspergillus, and fatal candidal 
sepsis, and fatal pneumocystis carinii, in particular. Because Everolimus, as other rapamycins, 
inhibits proliferation of activated lymphocytes and reduces neutrophil counts, treatment with 
Everolimus must be considered as predisposing patients to the risk of infection. This risk will be 
higher in patients severely immunocompromised because of their underlying disease and/or co- 
medications. Outcome may be fatal in case of serious infections. 
 
A reduction in blood cell counts is frequent when Everolimus therapy is initiated. Without clinical 
significance and infrequently, anemia and thrombocytopenia have been reported. In heavily 
pretreated patients with aggressive lymphoma, the incidence of grade 3 anemia, neutropenia, and 
thrombocytopenia was reported to be 11%, 16%, and 30%, respectively. Serious, suspected drug- 
related hemorrhages have been exceptional. Nevertheless, Everolimus should be considered as 
predisposing patients to hemorrhage, potentially fatal, should they develop severe drug-related 
thrombocytopenia. 
 
Discrete, reversible changes in liver enzymes have been found to occur in numerous patients during 
treatment with Everolimus in oncology clinical studies and in a study in rheumatoid arthritis. In 
oncology studies, these changes may be evident only in patients without severe underlying morbidity. 
The increase in aspartate transaminase (AST) and alanine transaminase (ALT) generally appears 
after 4 weeks of treatment. In all but a few cases it does not exceed grade 1 (≤2.5 x ULN). Similarly, 
mild increases in alkaline phosphatases can coexist. Spontaneous corrections or intermittent 
correction with continued treatment can occur. Serum bilirubin is not increased. In studies of patients 
with advanced cancers, clinically relevant changes in liver enzymes have been invariably associated 
with the presence of liver metastases and/or progression of the underlying cancer. 
 
Renal failure has been reported in 5 suspected cases to date. One patient with no alternative 
explanation made a complete recovery following study drug adjustment and no treatment/therapy for 
the event. The rest of the patients had concurrent morbidities, which might have contributed to the 
reported events. 
 
Hypophosphatemia, hypomagnesemia, hyponatremia, and hypocalcemia have been reported as 
serious adverse reactions. Electrolytes should be monitored in patients treated with Everolimus. 
More detailed information regarding Everolimus reported suspected toxicities and individual cases is 
provided in the [Investigator’s Brochure]. 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 47 of 62 
 
 
 
 
 
12.0CRITERIA FOR THERAPEUTIC RESPONSE/OUTCOME ASSESSMENT 
 
Complete response (CR) is defined as no evidence of disease (by cytology and cystoscopy). 
Progression is defined as the development of invasion or metastasis. If the patient develops a 
recurrence, they will be considered having failed treatment. Patients will also be considered having 
failed treatment if there is no response to treatment after two cycles. 
 
 
Patients will receive cystoscopy and cytology every 3 months. If a suspicious or positive cystoscopy 
or cytology is found, then a TUR will be performed no later than 4 weeks from the suspicious/positive 
test to determine presence or absence of disease. For purposes of the primary endpoint, patients 
demonstrating a CR at 11 months will undergo cystoscopy and cytology (and if suspicious, then a 
TUR) between 11 and 13 months. 
 
 
13.0CRITERIA FOR REMOVAL FROM STUDY 
 
If at any time the patient develops progressive disease he/she will be taken off study and referred for 
alternative therapy. 
 
If at any time the patient develops unacceptable toxicity he/she will be removed from study. 
 
If at any point a patient develops any grade 4 toxicity suspected to be related to gemcitabine, the 
patient will be taken off study. 
 
If a patient requires a dose delay from Everolimus of >21 days from the intended day of the next 
scheduled dose, then the patient must be discontinued from the study. 
If the patient requires a dose delay from gemcitabine of >14 days, the patient will be taken off study. 
If at anytime the patient is found to be ineligible for the protocol as designated in the section on 
Criteria for Patient/Subject Eligibility (i.e., a change in diagnosis), the patient will be removed from 
the study. 
 
Patients who are removed from study due to withdrawal of consent, lost to follow-up, or 
administrative problems should not be considered unevaluable and will be replaced. 
 
 
 
14.0BIOSTATISTICS 
 
Basis for sample size 
 
Phase I: Patients will be accrued in the standard 3+3 fashion such that the MTD is the dose level at 
which no more than 1 out of 6 patients experience DLT. This portion will accrue between 2 and 18 
patients. 
 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 48 of 62 
 
 
Phase II: The purpose of this phase of the study is to assess the efficacy of gemcitabine plus 
Everolimus in patients with BCG-refractory disease. The primary endpoint will be the proportion of 
patients who are disease-free at 1 year following start of therapy. 
 
Historically, only about 10% of patients in this setting will be disease-free 1 year following therapy, 
therefore a 1-year disease-free rate of 10% would be considered not promising, while a 30% rate 
would be considered promising. We have chosen a single-stage design and set the type I (falsely 
accepting a non-promising therapy) and type II error (falsely rejecting a promising therapy) rates at 
0.05 and 0.10, respectively. This portion of the study will enroll 33 patients (6 can be carried over 
from the MTD cohort of the phase I portion). If there are 7 or more who are disease-free at 1 year, 
the treatment will be declared effective and worthy of further testing. 
 
In order to confirm the safety of the regimen, patients will continuously be monitored for excessive 
toxicity and early stopping rules for toxicity will be employed. Unacceptable toxicity is defined as any 
grade 3 or higher local toxicity including hematuria, urgency, and frequency. Stopping rules and the 
corresponding power calculations are provided in the table below. 
 
Table 14-1 
Number of toxicities needed to 
stop the study 
True probability of toxicity in 
the populations 
Probability of study 
completion (based on 
projection) 
1 in the first 7 patients 
2 in the first 16 patients 
3 in the first 28 patients 
4 in all 33 patients 
0.05 
0.91 
0.11 
0.54 
0.20 
0.11 
 
 
Secondary endpoints 
 
a)  To determine the CR rate (by cytology and cystoscopy) in patients receiving Everolimus in 
combination with intravesical gemcitabine. We will calculate the proportion of patients who 
demonstrate CR at any time within the year following start of therapy, with a 95% confidence 
interval. With 33 patients, we will be able to estimate this proportion within +/- 18%. 
 
b)  To determine the survival of patients treated with Everolimus in combination with intravesical 
gemcitabine. Overall survival following start of therapy will be estimated using Kaplan-Meier 
methods. 
 
c)  To evaluate for activated mTOR pathway markers as well as PTEN status and AKT 
activation in all pretreatment and analysis of posttreatment specimens when available. These 
analyses will be descriptive in nature and will be used to generate hypotheses for future 
studies. mTOR and PTEN status will be summarized descriptively, overall and separately for 
those with and without a CR. 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 49 of 62 
 
 
Patients removed from protocol therapy for reasons other than disease progression, death, or 
toxicity prior to one year will not be evaluable for the primary end-point and will be replaced. 
However, these patients may still be evaluable for the secondary end-points. 
 
 
 
15.0 RESEARCH PARTICIPANT REGISTRATION AND RANDOMIZATION PROCEDURES 
 
15.1Research Participant Registration 
Confirm eligibility as defined in the section entitled Criteria for Patient/Subject Eligibility. 
Obtain written informed consent, by following procedures defined in section entitled Informed 
Consent Procedures. 
 
All participants must be registered through the Protocol Participant Registration (PPR) Office at 
Memorial Sloan-Kettering Cancer Center. PPR is available Monday through Friday from 8:30am – 
5:30pm at 646-735-8000. The PPR fax numbers are (646) 735-0008 and (646) 735-0003. 
Registrations can be phoned in or faxed. The completed signature page of the informed consent 
form, the completed signature page of the Research Authorization and a completed Eligibility 
Checklist must be faxed to PPR. 
 
During the registration process registering individuals will be required to answer specific eligibility 
questions and provide the following information: 
 
Registering Individual [Last, First Name] 
Research Authorization [Date] 
MSKCC IRB Protocol# 
Attending of Record (if applicable)[Last, First Name] 
Consenting Professional [Last, First Name] 
Informed Consent Date 
Participant’s Full Name [Last, First Name] 
Participant MRN 
 
 
 
15.2Randomization 
 
Not applicable 
 
16.0DATA MANAGEMENT ISSUES 
 
A Research Study Assistant (RSA) will be assigned to the study. The responsibilities of the RSA 
include project compliance, data collection, abstraction and entry, data reporting, regulatory 
monitoring, problem resolution and prioritization, and coordination of the activities of the protocol 
study team. 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 50 of 62 
 
 
The data collected for this study will be entered into a secure database. Source documentation will 
be available to support the computerized patient record. 
 
16.1Quality Assurance 
 
 
 
Monthly registration reports will be generated to monitor patient accruals and completeness of 
registration data. Routine data quality reports will be generated to assess missing data and 
inconsistencies. Accrual rates and extent and accuracy of evaluations and follow-up will be 
monitored periodically throughout the study period and potential problems will be brought to the 
attention of the study team for discussion and action. Random-sample data quality and protocol 
compliance audits will be conducted by the study team at a minimum of two times per year, more 
frequently if indicated. 
 
16.2Data and Safety Monitoring 
 
 
The Data and Safety Monitoring (DSM) Plans at Memorial Sloan-Kettering Cancer Center were 
approved by the National Cancer Institute in September 2001. The plans address the new policies 
set forth by the NCI in the document entitled “Policy of the National Cancer Institute for Data and 
Safety Monitoring of Clinical Trials,” which can be found at: 
http://cancertrials.nci.nih.gov/researchers/dsm/index.html. The DSM Plans at MSKCC were 
established and are monitored by the Office of Clinical Research. The MSKCC Data and Safety 
Monitoring Plans can be found on the MSKCC Intranet at: http://mskweb2.mskcc.org /irb/index.htm 
 
 
There are several different mechanisms by which clinical trials are monitored for data, safety and 
quality. There are institutional processes in place for quality assurance (e.g., protocol monitoring, 
compliance and data verification audits, therapeutic response, and staff education on clinical 
research QA) and departmental procedures for quality control, plus there are two institutional 
committees that are responsible for monitoring the activities of our clinical trials programs. The 
committees, Data and Safety Monitoring Committee (DSMC) for Phase I and II clinical trials and the 
Data and Safety Monitoring Board (DSMB) for Phase III clinical trials, report to the Center’s 
Research Council and Institutional Review Board. 
 
During the protocol development and review process, each protocol will be assessed for its level of 
risk and degree of monitoring required. Every type of protocol (e.g., NIH sponsored, in-house 
sponsored, industrial sponsored, NCI cooperative group, etc.) will be addressed and the monitoring 
procedures will be established at the time of protocol activation. 
 
17.0PROTECTION OF HUMAN SUBJECTS 
 
17.1Privacy 
 
MSKCC’s Privacy Office may allow the use and disclosure of protected health information pursuant 
to a completed and signed Research Authorization form. The use and disclosure of protected health 
information will be limited to the individuals described in the Research Authorization form. A 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 51 of 62 
 
 
Research Authorization form must be completed by the Principal Investigator and approved by the 
IRB and Privacy Board (IRB/PB). 
17.2Serious Adverse Event (SAE) Reporting 
 
Any SAE must be reported to the IRB/PB as soon as possible but no later than 5 calendar days. The 
IRB/PB requires a Clinical Research Database (CRDB) SAE report be submitted electronically to the 
SAE Office at sae@mskcc.org containing the following information: 
 
 
Fields populated from CRDB: 
 
• 
Subject’s name (generate the report with only initials if it will be sent outside of 
MSKCC) 
• 
Medical record number 
• 
Disease/histology (if applicable) 
• 
Protocol number and title 
 
Data needing to be entered: 
 
• 
The date the adverse event occurred 
• 
The adverse event 
• 
Relationship of the adverse event to the treatment (drug, device, or intervention) 
• 
If the AE was expected 
• 
The severity of the AE 
• 
The intervention 
• 
Detailed text that includes the following 
o A explanation of how the AE was handled 
o A description of the subject’s condition 
o Indication if the subject remains on the study 
o If an amendment will need to be made to the protocol and/or consent form. 
The PI’s signature and the date it was signed are required on the completed report. 
For IND/IDE protocols: 
The CRDB AE report should be completed as above and the FDA assigned IND/IDE number 
written at the top of the report. The report will be forwarded to the FDA by the Institutional 
SAE Manager through the IND Office. 
 
17.2.1Serious Adverse Event (SAE) Reporting to Novartis 
 
The Principal Investigator has the obligation to report all serious adverse events to the IRB, and 
Novartis Pharmaceuticals Clinical Safety and Epidemiology Department (CS&E). 
 
All events must be reported, by Fax (888-299-4565) to Novartis Pharmaceuticals CS&E 
Department within 24 hours of learning of its occurrence. This includes serious, related, labeled 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 52 of 62 
 
 
(expected) and serious, related, unlabeled (unexpected) adverse experiences. All deaths during 
treatment or within 30 days following completion of active protocol therapy must be reported within 5 
working days. 
 
Any serious adverse event occurring after the patient has provided informed consent and until 4 
weeks after the patient has stopped study participation must be reported. This includes the period in 
which the study protocol interferes with the standard medical treatment given to a patient (e.g. 
treatment withdrawal during washout period, change in treatment to a fixed dose of concomitant 
medication). 
 
Serious adverse events occurring more than 4 weeks after study discontinuation need only be 
reported if a relationship to the Novartis study drug (or therapy) is suspected. 
 
For Comparator Drugs/Secondary Suspects (Concomitant Medications), all serious adverse 
experiences will be forwarded to the product manufacturer by the investigator. 
 
Any pregnancy that occurs during study participation should be reported. To ensure patient safety, 
each pregnancy must also be reported to Novartis within 24 hours of learning of its occurrence. The 
pregnancy should be followed up to determine outcome, including spontaneous or voluntary 
termination, details of birth, and the presence or absence of any birth defects, congenital 
abnormalities, or maternal and newborn complications. 
 
 
 
18.0INFORMED CONSENT PROCEDURES 
 
Patients will be required to sign a statement of informed consent which meets the 
requirements of code of Federal Regulations (Federal Register Vol. 46, No. 17, Jan. 27, 1981, part 
50) and the IRB of this center. 
 
 
Consent Process: The consenting professional will review the rationale for the treatment program 
with the patient. The discussion will review the alternatives available, including supportive care as 
appropriate, the potential benefits of this program, the risks and the probability of their occurrence, 
and the procedures to minimize these risks. The provisions available to ensure medical intervention 
should an adverse event occur will also be reviewed. Whether the risks are reasonable in relation to 
the anticipated benefits, incentives, costs that will or may be incurred as a result of participation in 
the study, and efforts to maintain the confidentiality of research participants will also be discussed. 
 
At the time of registration, the eligibility checklist will be reviewed, verified, and signed. 
MSKCC Physicians Eligible to Register Patients: Final informed consent may be obtained by the 
consenting professionals listed on the protocol face sheet. 
 
 
Documentation of Informed Consent: The informed consent will be signed by the patient and 
consenting professional in triplicate. A signed original copy of the consent form will be given to the 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 53 of 62 
 
 
patient. The second original will be placed in the medical record, and the third original will be kept in 
the research file. 
 
18.1Research Authorization 
 
Procedures for obtaining Research Authorization: Before any protocol-specific procedures are 
carried out, investigators and/or designated staff will fully explain the details of the protocol, study 
procedures, and the aspects of patient privacy concerning research specific information. In addition 
to signing the IRB Informed Consent, all patients must sign the Research Authorization component 
of the informed consent form. The Research Authorization requires a separate set of signatures from 
the patient. The original signed documents will become part of the patient’s medical record, and 
each patient will receive a copy of the signed documents. 
 
19.0 
REFERENCES 
 
1, 
Boulay A and Lane HA. The mammalian target of rapamycin kinase and tumor 
growth inhibition. 2007 Recent Results Cancer Res 172: 99-124. 
 
2. 
Bjornsti MA and Houghton PJ. The TOR pathway: a target for cancer therapy. 2004 
Nat Rev Cancer 4: 335-48. 
 
3. 
Wullschleger S, Loewith R and Hall MN. TOR signaling in growth and metabolism. 
2006 Cell 124: 471-84. 
 
4. 
Manning BD and Cantley LC. AKT/PKB signaling: navigating downstream. 2007 Cell 
129: 1261-74. 
 
5. 
Wang L, Harris TE, Roth RA and Lawrence JC, Jr. PRAS40 regulates mTORC1 
kinase activity by functioning as a direct inhibitor of substrate binding. 2007 J Biol 
Chem 282: 20036-44. 
 
6. 
Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P, Ansell SM, Luyun 
R, Flynn PJ, Morton RF, Dakhil SR, Gross H and Kaufmann SH. Phase II trial of 
single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. 2005 J Clin 
Oncol 23: 5347-56. 
 
7. 
Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH and 
Auernhammer CJ. The novel mTOR inhibitor RAD001 (everolimus) induces 
antiproliferative effects in human pancreatic neuroendocrine tumor cells. 2007 
Neuroendocrinology 85: 54-60. 
 
8. 
Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles 
FJ, Sabatini DM, Andreeff M and Konopleva M. Rapamycin derivatives reduce 
mTORC2 signaling and inhibit AKT activation in AML. 2007 Blood 109: 3509-12. 
 
9. 
Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, Takeuchi T, 
Koeffler HP and Taguchi H. Longitudinal inhibition of PI3K/Akt/mTOR signaling by 
LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. 2007 
Leuk Res 31: 673-82. 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 54 of 62 
 
 
10. 
Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C and Decker T. 
Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B 
cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. 2006 Br J 
Haematol 134: 475-84. 
 
11. 
Tuncyurek P, Mayer JM, Klug F, Dillmann S, Henne-Bruns D, Keller F and Stracke S. 
Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to 
gemcitabine in vitro: a novel adjunct to standard chemotherapy? 2007 Eur Surg Res 
39: 380-7. 
 
12. 
Treeck O, Wackwitz B, Haus U and Ortmann O. Effects of a combined treatment with 
mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human 
cancer cells. 2006 Gynecol Oncol 102: 292-9. 
 
13. 
Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder 
RJ, Ozols RF and Testa JR. RAD001 inhibits human ovarian cancer cell proliferation, 
enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer 
model. 2007 Clin Cancer Res 13: 4261-70. 
 
14. 
Sieghart W, Fuereder T, Schmid K, Cejka D, Werzowa J, Wrba F, Wang X, Gruber D, 
Rasoul-Rockenschaub S, Peck-Radosavljevic M and Wacheck V. Mammalian target 
of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing 
liver transplantation. 2007 Transplantation 83: 425-32. 
 
15. 
Haritunians T, Mori A, O'Kelly J, Luong QT, Giles FJ and Koeffler HP. 
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with 
other agents in mantle cell lymphoma. 2007 Leukemia 21: 333-9. 
 
16. 
Lane H, Tanaka C and Kovarik J. Preclinical and clinical pharmacokinetic / 
pharmacodynamic (PK/PD) modeling to help define an optimal biological dose for the 
oral mTOR inhibitor, RAD001, in oncology. 2003 J Clin Oncol 22: 237A. 
 
17. 
Tabernero J, Rojo F and Casado Eea. A phase 1 study with tumor molecular 
pharmacodynamic evaluation of dose and schedule of the oral mTOR inhibitor 
everlolimus (RAD001) in patients with advanced solid tumors. 2005 J Clin Oncol 23: 
3007. 
 
18. 
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, 
Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D 
and Ravaud A. Efficacy of everolimus in advanced renal cell carcinoma: a double- 
blind, randomised, placebo-controlled phase III trial. 2008 Lancet 372: 449-56. 
 
19. 
Kay A, Motzer R, Figlin R, Escudier B, Oudard S, Porta C, Hutson T, Bracarda S, 
Hollaender N, Urbanowitz G and Ravaud A. Updated data from a phase III 
randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell 
carcinoma (mRCC). Abstract 278. Genitourinary Cancers Symposium. Orlando, 
Florida. Feb. 26-28, 2009. 
 
20. 
Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB. 
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). 
1990 Cancer Res 50: 4417-22. 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 55 of 62 
 
 
21. 
Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, 
Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens 
CD and Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine 
as first-line therapy for patients with advanced pancreas cancer: a randomized trial. 
1997 J Clin Oncol 15: 2403-13. 
 
22. 
Moore MJ, Tannock IF, Ernst DS, Huan S and Murray N. Gemcitabine: a promising 
new agent in the treatment of advanced urothelial cancer. 1997 J Clin Oncol 15: 
3441-5. 
 
23. 
Stadler WM, Kuzel T, Roth B, Raghavan D and Dorr FA. Phase II study of single- 
agent gemcitabine in previously untreated patients with metastatic urothelial cancer. 
1997 J Clin Oncol 15: 3394-8. 
 
24. 
Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini 
M and De Lena M. A phase II study of gemcitabine in patients with transitional cell 
carcinoma of the urinary tract previously treated with platinum. Italian Co-operative 
Group on Bladder Cancer. 1998 Eur J Cancer 34: 1208-12. 
 
25. 
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi 
I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, 
Roychowdhury DF, Tomlin I, Visseren-Grul CM and Conte PF. Gemcitabine and 
cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or 
metastatic bladder cancer: results of a large, randomized, multinational, multicenter, 
phase III study. 2000 J Clin Oncol 18: 3068-77. 
 
26. 
Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, 
Herr HW, Sogani P, dePalma D and Bajorin D. Phase I trial of intravesical 
gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the 
bladder. 2002 J Clin Oncol 20: 3193-8. 
 
27. 
Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, Donat MS, 
Herr HW and Bajorin D. Phase II trial of intravesical gemcitabine in bacille Calmette- 
Guerin-refractory transitional cell carcinoma of the bladder. 2006 J Clin Oncol 24: 
2729-34. 
 
28. 
Laufer M, Ramalingam S, Schoenberg MP, Haisfield-Wolf ME, Zuhowski EG, 
Trueheart IN, Eisenberger MA, Nativ O and Egorin MJ. Intravesical gemcitabine 
therapy for superficial transitional cell carcinoma of the bladder: a phase I and 
pharmacokinetic study. 2003 J Clin Oncol 21: 697-703. 
 
29. 
De Berardinis E, Antonini G, Peters GJ, Loves WJ, Van der Born K, Codacci-Pisanelli 
G and Di Silverio F. Intravesical administration of gemcitabine in superficial bladder 
cancer: a phase I study with pharmacodynamic evaluation. 2004 BJU Int 93: 491-4. 
 
30. 
Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ. Cancer statistics, 2009. 2009 
CA Cancer J Clin 59: 225-49. 
 
31. 
Soloway MS. Overview of treatment of superficial bladder cancer. 1985 Urology 26: 
18-26. 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 56 of 62 
 
 
32. 
Surveillance, initial assessment, and subsequent progress of patients with superficial 
bladder cancer in a prospective longitudinal study. National Bladder Cancer 
Collaborative Group A (NBCCGA). 1977 Cancer Res 37: 2907-10. 
 
33. 
Herr HW, Jakse G and Sheinfeld J. The T1 bladder tumor. 1990 Semin Urol 8: 254- 
61. 
 
34. 
Milowsky MI, Tickoo SK, Gallagher DJ, Bajorin DF and Reuter VE. HIF and mTOR 
pathways in invasive urothelial carcinoma: A study with potential therapeutic 
implications. Abstract 292. Genitourinary Cancers Symposium. San Francisco, 
California. Feb. 14-17, 2008. 
 
35. 
Neshat M, Mellinghoff I, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons 
JJ, Wu H and Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to 
inhibition of FRAP/mTOR. 2001 Proc Natl Acad Sci USA 98: 10314-9. 
 
36. 
Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H and Morrison SJ. 
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating 
cells. 2006 Nature 441: 475-82. 
 
37. 
Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, Puc J, Neshat M, Wang H, 
Yang L, Gibbons J, Frost P, Dreisbach V, Blenis J, Gaciong Z, Fisher P, Sawyers C, 
Hedrick-Ellenson L and Parsons R. An inhibitor of mTOR reduces neoplasia and 
normalizes p70/S6 kinase activity in Pten+/- mice. 2001 Proc Natl Acad Sci USA 98: 
10320-5. 
 
38. 
Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, 
Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA and Sellers WR. mTOR 
inhibition reverses Akt-dependent prostate intraepithelial neoplasia through 
regulation of apoptotic and HIF-1-dependent pathways. 2004 Nat Med 10: 594-601. 
 
39. 
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen 
Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, 
Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK and Sawyers CL. 
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN- 
deficient glioblastoma. . 2008 PLoS Med 5: e8. 
 
40. 
Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou 
SH, Marshall B, Boni JP, Dukart G and Sherman ML. Randomized phase II study of 
multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase 
inhibitor, in patients with advanced refractory renal cell carcinoma. 2004 J Clin Oncol 
22: 909-18. 
 
41. 
Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F and Csako G. 
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation 
during chemotherapy. 2008 Ann Intern Med 148: 519-28. 
 
42. 
Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M and McLeod J. Effects 
of oral posaconazole on the pharmacokinetic properties of oral and intravenous 
midazolam: A phase I, randomized, open-label, crossover study in healthy 
volunteers. 2009 Clin Ther 31: 286-98. 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 57 of 62 
 
 
 
 
 
20.0 
APPENDICES 
 
Appendix 1: Everolimus (RAD001) Continuous Cycle Schedule Treatment Log (5mg every other 
day) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended: 1/11/11 

MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
Page 58 of 62 
 
 
Patient Name:  
 
Patient MRN:  
 
Protocol 10-165: Phase I/II Study of Everolimus and Intravesical Gemcitabine in BCG- 
Refractory Primary or Secondary Carcinoma In Situ of the Bladder 
EVEROLIMUS (RAD001) CONTINUOUS CYCLE SCHEDULE TREATMENT LOG 
Place a check in the box next to the date you take this medication. 
Please bring this sheet to your study doctor's office on each visit 
Cycle:    
 
Date 
Day 
Time 
Treatment 
Dose 
Questions for Study Doctor/Nurse 
1 
Everolimus     5 mg 
2 
3 
Everolimus    
4 
5 
Everolimus    
6 
7 
Everolimus    
8 
9 
Everolimus    
10 
11 
Everolimus    
12 
13 
Everolimus    
14 
15 
Everolimus    
16 
17 
Everolimus    
18 
19 
Everolimus    
20 
 
 
Amended: 1/11/11 

Page 59 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
21 
Everolimus    
22 
23 
Everolimus    
24 
25 
Everolimus    
26 
27 
Everolimus    
28 
MD/RN 
Signature:  
 
Date:  
 
Tablets Remaining:_  
 
Comments:_  
 
 
 
 
 
 
Appendix 2: Everolimus (RAD001) Continuous Cycle Schedule Treatment Log (5 mg every day) 
 
Patient Name  
 
Patient MRN:  
 
Protocol 10-165: Phase I/II Study of Everolimus and Intravesical Gemcitabine in BCG- 
Refractory Primary or Secondary Carcinoma In Situ of the Bladder 
EVEROLIMUS (RAD001) CONTINUOUS CYCLE SCHEDULE TREATMENT LOG 
Place a check in the box next to the date you take this medication. 
Please bring this sheet to your study doctor's office on each visit 
Cycle:    
 
Date 
Day 
Time 
Treatment 
Dose 
Questions for Study Doctor/Nurse 
1 
Everolimus    
5 mg 
2 
Everolimus    
3 
Everolimus    
4 
Everolimus    
5 
Everolimus    
6 
Everolimus    
7 
Everolimus    
 
Amended: 1/11/11 

Page 60 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
8 
Everolimus    
9 
Everolimus    
10 
Everolimus    
11 
Everolimus    
12 
Everolimus    
13 
Everolimus    
14 
Everolimus    
15 
Everolimus    
16 
Everolimus    
17 
Everolimus    
18 
Everolimus    
19 
Everolimus    
20 
Everolimus    
21 
Everolimus    
22 
Everolimus    
23 
Everolimus    
24 
Everolimus    
25 
Everolimus    
26 
Everolimus    
27 
Everolimus    
28 
Everolimus    
MD/RN 
Signature:  
 
Date_  
 
Tablets Remaining  
 
Comments:_  
 
 
 
Appendix 3: Everolimus (RAD001) Continuous Cycle Schedule Treatment Log (10 mg every day) 
 
Amended: 1/11/11 

Page 61 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
Patient Name:  
 
Patient MRN:  
 
Protocol 10-165: Phase I/II Study of Everolimus and Intravesical Gemcitabine in BCG- 
Refractory Primary or Secondary Carcinoma In Situ of the Bladder 
EVEROLIMUS (RAD001) CONTINUOUS CYCLE SCHEDULE TREATMENT LOG 
Place a check in the box next to the date you take this 
medication. Please bring this sheet to your study 
doctor's office on each visit 
Cycle:    
 
Date 
Day 
Time 
Treatment 
Dose 
Questions for Study Doctor/Nurse 
1 
Everolimus    
10 mg 
2 
Everolimus    
3 
Everolimus    
4 
Everolimus    
5 
Everolimus    
6 
Everolimus    
7 
Everolimus    
8 
Everolimus    
9 
Everolimus    
10 
Everolimus    
11 
Everolimus    
12 
Everolimus    
13 
Everolimus    
14 
Everolimus    
15 
Everolimus    
16 
Everolimus    
17 
Everolimus    
18 
Everolimus    
19 
Everolimus    
20 
Everolimus    
 
Amended: 1/11/11 

Page 62 of 62 
MEMORIAL SLOAN-KETTERING CANCER CENTER 
IRB PROTOCOL 
IRB#: 10-165A(1) 
 
 
21 
Everolimus    
22 
Everolimus    
23 
Everolimus    
24 
Everolimus    
25 
Everolimus    
26 
Everolimus    
27 
Everolimus    
28 
Everolimus    
MD/RN 
Signature:  
 
Date_  
 
Tablets 
Remaining  
 
Comments:_  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended: 1/11/11